type: Article
authors:
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Biomolecular Sciences, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Warszawski
    givenNames:
      - Shira
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Structural Biology, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Borenstein
      - Katz
    givenNames:
      - Aliza
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Biomolecular Sciences, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Lipsh
    givenNames:
      - Rosalie
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Structural Biology, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Khmelnitsky
    givenNames:
      - Lev
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Biomolecular Sciences, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Ben
      - Nissan
    givenNames:
      - Gili
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Structural Biology, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Javitt
    givenNames:
      - Gabriel
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Israel Structural Proteomics Center, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Dym
    givenNames:
      - Orly
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Israel Structural Proteomics Center, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Unger
    givenNames:
      - Tamar
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Biomolecular Sciences, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Knop
    givenNames:
      - Orli
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Israel Structural Proteomics Center, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Albeck
    givenNames:
      - Shira
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Structural Biology, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Diskin
    givenNames:
      - Ron
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Structural Biology, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Fass
    givenNames:
      - Deborah
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Biomolecular Sciences, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Sharon
    givenNames:
      - Michal
  - type: Person
    affiliations:
      - type: Organization
        name: >-
          Department of Biomolecular Sciences, Weizmann Institute of Science,
          Rehovot, Israel
    familyNames:
      - Fleishman
    givenNames:
      - Sarel
      - J.
dateAccepted:
  type: Date
  value: '2019-06-21'
datePublished:
  type: Date
  value: '2019-08-23'
dateReceived:
  type: Date
  value: '2019-02-03'
description:
  - type: Paragraph
    content:
      - >-
        Antibodies developed for research and clinical applications may exhibit
        suboptimal stability, expressibility, or affinity. Existing optimization
        strategies focus on surface mutations, whereas natural affinity
        maturation also introduces mutations in the antibody core,
        simultaneously improving stability and affinity. To systematically map
        the mutational tolerance of an antibody variable fragment (Fv), we
        performed yeast display and applied deep mutational scanning to an
        anti-lysozyme antibody and found that many of the affinity-enhancing
        mutations clustered at the variable light-heavy chain interface, within
        the antibody core. Rosetta design combined enhancing mutations, yielding
        a variant with tenfold higher affinity and substantially improved
        stability. To make this approach broadly accessible, we developed
        AbLIFT, an automated web server that designs multipoint core mutations
        to improve contacts between specific Fv light and heavy chains (
      - type: Link
        target: 'http://ablift.weizmann.ac.il/'
        content:
          - 'http://AbLIFT.weizmann.ac.il'
      - >-
        ). We applied AbLIFT to two unrelated antibodies targeting the human
        antigens VEGF and QSOX1. Strikingly, the designs improved stability,
        affinity, and expression yields. The results provide proof-of-principle
        for bypassing laborious cycles of antibody engineering through automated
        computational affinity and stability design.
editors:
  - type: Person
    affiliations:
      - type: Organization
        name: 'Koç University, TURKEY'
    familyNames:
      - Keskin
    givenNames:
      - Ozlem
identifiers:
  - type: PropertyValue
    name: doi
    propertyID: 'https://registry.identifiers.org/registry/doi'
    value: 10.1371/journal.pcbi.1007207
  - type: PropertyValue
    name: publisher-id
    propertyID: 'https://registry.identifiers.org/registry/publisher-id'
    value: PCOMPBIOL-D-19-00192
  - type: PropertyValue
    name: elocation-id
    propertyID: 'https://registry.identifiers.org/registry/elocation-id'
    value: e1007207
isPartOf:
  type: PublicationVolume
  isPartOf:
    type: Periodical
    identifiers:
      - type: PropertyValue
        name: nlm-ta
        propertyID: 'https://registry.identifiers.org/registry/nlm-ta'
        value: PLoS Comput Biol
      - type: PropertyValue
        name: publisher-id
        propertyID: 'https://registry.identifiers.org/registry/publisher-id'
        value: plos
      - type: PropertyValue
        name: pmc
        propertyID: 'https://registry.identifiers.org/registry/pmc'
        value: ploscomp
    issns:
      - 1553-734X
      - 1553-7358
    publisher:
      type: Organization
      name: Public Library of Science
    title: PLOS Computational Biology
  volumeNumber: '15'
licenses:
  - type: CreativeWork
    url: 'http://creativecommons.org/licenses/by/4.0/'
    content:
      - type: Paragraph
        content:
          - 'This is an open access article distributed under the terms of the '
          - type: Link
            target: 'http://creativecommons.org/licenses/by/4.0/'
            content:
              - Creative Commons Attribution License
          - >-
            , which permits unrestricted use, distribution, and reproduction in
            any medium, provided the original author and source are credited.
references:
  - type: Article
    id: pcbi-1007207-ref001
    authors:
      - type: Person
        familyNames:
          - Acierno
        givenNames:
          - JP
      - type: Person
        familyNames:
          - Braden
        givenNames:
          - BC
      - type: Person
        familyNames:
          - Klinke
        givenNames:
          - S
      - type: Person
        familyNames:
          - Goldbaum
        givenNames:
          - FA
      - type: Person
        familyNames:
          - Cauerhff
        givenNames:
          - A
    datePublished: '2007'
    isPartOf:
      type: PublicationVolume
      pageEnd: 146
      pageStart: 130
      title: J Mol Biol
      volumeNumber: 374
    title: >-
      Affinity Maturation Increases the Stability and Plasticity of the Fv
      Domain of Anti-protein Antibodies
  - type: Article
    id: pcbi-1007207-ref002
    authors:
      - type: Person
        familyNames:
          - Saxena
        givenNames:
          - V
      - type: Person
        familyNames:
          - Panicucci
        givenNames:
          - R
      - type: Person
        familyNames:
          - Joshi
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Garad
        givenNames:
          - S
    datePublished: '2009'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1979
      pageStart: 1962
      title: Journal of Pharmaceutical Sciences
    title: >-
      Developability assessment in pharmaceutical industry: An integrated group
      approach for selecting developable candidates
  - type: Article
    id: pcbi-1007207-ref003
    authors:
      - type: Person
        familyNames:
          - Chao
        givenNames:
          - G
      - type: Person
        familyNames:
          - Lau
        givenNames:
          - WL
      - type: Person
        familyNames:
          - Hackel
        givenNames:
          - BJ
      - type: Person
        familyNames:
          - Sazinsky
        givenNames:
          - SL
      - type: Person
        familyNames:
          - Lippow
        givenNames:
          - SM
      - type: Person
        familyNames:
          - Wittrup
        givenNames:
          - KD
    datePublished: '2006'
    isPartOf:
      type: PublicationVolume
      pageEnd: 768
      pageStart: 755
      title: Nat Protoc
      volumeNumber: 1
    title: Isolating and engineering human antibodies using yeast surface display
  - type: Article
    id: pcbi-1007207-ref004
    authors:
      - type: Person
        familyNames:
          - Boder
        givenNames:
          - ET
      - type: Person
        familyNames:
          - Midelfort
        givenNames:
          - KS
      - type: Person
        familyNames:
          - Wittrup
        givenNames:
          - KD
    datePublished: '2000'
    isPartOf:
      type: PublicationVolume
      pageEnd: 10705
      pageStart: 10701
      title: Proc Natl Acad Sci U S A
      volumeNumber: 97
    title: >-
      Directed evolution of antibody fragments with monovalent femtomolar
      antigen-binding affinity
  - type: Article
    id: pcbi-1007207-ref005
    authors:
      - type: Person
        familyNames:
          - Midelfort
        givenNames:
          - KS
      - type: Person
        familyNames:
          - Hernandez
        givenNames:
          - HH
      - type: Person
        familyNames:
          - Lippow
        givenNames:
          - SM
      - type: Person
        familyNames:
          - Tidor
        givenNames:
          - B
      - type: Person
        familyNames:
          - Drennan
        givenNames:
          - CL
      - type: Person
        familyNames:
          - Wittrup
        givenNames:
          - KD
    datePublished: '2004'
    isPartOf:
      type: PublicationVolume
      pageEnd: 701
      pageStart: 685
      title: J Mol Biol
      volumeNumber: 343
    title: >-
      Substantial energetic improvement with minimal structural perturbation in
      a high affinity mutant antibody
  - type: Article
    id: pcbi-1007207-ref006
    authors:
      - type: Person
        familyNames:
          - Julian
        givenNames:
          - MC
      - type: Person
        familyNames:
          - Li
        givenNames:
          - L
      - type: Person
        familyNames:
          - Garde
        givenNames:
          - S
      - type: Person
        familyNames:
          - Wilen
        givenNames:
          - R
      - type: Person
        familyNames:
          - Tessier
        givenNames:
          - PM
    datePublished: '2017'
    isPartOf:
      type: PublicationVolume
      pageStart: 45259
      title: Sci Rep
      volumeNumber: 7
    title: >-
      Efficient affinity maturation of antibody variable domains requires
      co-selection of compensatory mutations to maintain thermodynamic stability
  - type: Article
    id: pcbi-1007207-ref007
    authors:
      - type: Person
        familyNames:
          - Ponsel
        givenNames:
          - D
      - type: Person
        familyNames:
          - Neugebauer
        givenNames:
          - J
      - type: Person
        familyNames:
          - Ladetzki-Baehs
        givenNames:
          - K
      - type: Person
        familyNames:
          - Tissot
        givenNames:
          - K
    datePublished: '2011'
    isPartOf:
      type: PublicationVolume
      pageEnd: 3700
      pageStart: 3675
      title: Molecules
    title: >-
      High affinity, developability and functional size: The holy grail of
      combinatorial antibody library generation
  - type: Article
    id: pcbi-1007207-ref008
    authors:
      - type: Person
        familyNames:
          - Cromwell
        givenNames:
          - MEM
      - type: Person
        familyNames:
          - Hilario
        givenNames:
          - E
      - type: Person
        familyNames:
          - Jacobson
        givenNames:
          - F
    datePublished: '2006'
    isPartOf:
      type: PublicationVolume
      pageEnd: 9
      title: AAPS J
      volumeNumber: 8
    title: Protein aggregation and bioprocessing
  - type: Article
    id: pcbi-1007207-ref009
    authors:
      - type: Person
        familyNames:
          - Rosenberg
        givenNames:
          - AS
    datePublished: '2006'
    isPartOf:
      type: PublicationVolume
      pageEnd: 7
      title: AAPS J
      volumeNumber: 8
    title: 'Effects of protein aggregates: an immunologic perspective'
  - type: Article
    id: pcbi-1007207-ref010
    authors:
      - type: Person
        familyNames:
          - Yang
        givenNames:
          - X
      - type: Person
        familyNames:
          - Xu
        givenNames:
          - W
      - type: Person
        familyNames:
          - Dukleska
        givenNames:
          - S
      - type: Person
        familyNames:
          - Benchaar
        givenNames:
          - S
      - type: Person
        familyNames:
          - Mengisen
        givenNames:
          - S
      - type: Person
        familyNames:
          - Antochshuk
        givenNames:
          - V
    datePublished: '2013'
    isPartOf:
      type: PublicationVolume
      pageEnd: 794
      pageStart: 787
      title: MAbs
      volumeNumber: 5
    title: >-
      Developability studies before initiation of process development: improving
      manufacturability of monoclonal antibodies
  - type: Article
    id: pcbi-1007207-ref011
    authors:
      - type: Person
        familyNames:
          - Beck
        givenNames:
          - A
      - type: Person
        familyNames:
          - Wurch
        givenNames:
          - T
      - type: Person
        familyNames:
          - Bailly
        givenNames:
          - C
      - type: Person
        familyNames:
          - Corvaia
        givenNames:
          - 'N'
    datePublished: '2010'
    isPartOf:
      type: PublicationVolume
      pageEnd: 352
      pageStart: 345
      title: Nat Rev Immunol
      volumeNumber: 10
    title: >-
      Strategies and challenges for the next generation of therapeutic
      antibodies
  - type: Article
    id: pcbi-1007207-ref012
    authors:
      - type: Person
        familyNames:
          - Lippow
        givenNames:
          - SM
      - type: Person
        familyNames:
          - Wittrup
        givenNames:
          - KD
      - type: Person
        familyNames:
          - Tidor
        givenNames:
          - B
    datePublished: '2007'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1176
      pageStart: 1171
      title: Nat Biotechnol
      volumeNumber: 25
    title: >-
      Computational design of antibody-affinity improvement beyond in vivo
      maturation
  - type: Article
    id: pcbi-1007207-ref013
    authors:
      - type: Person
        familyNames:
          - Chennamsetty
        givenNames:
          - 'N'
      - type: Person
        familyNames:
          - Voynov
        givenNames:
          - V
      - type: Person
        familyNames:
          - Kayser
        givenNames:
          - V
      - type: Person
        familyNames:
          - Helk
        givenNames:
          - B
      - type: Person
        familyNames:
          - Trout
        givenNames:
          - BL
    datePublished: '2009'
    isPartOf:
      type: PublicationVolume
      pageEnd: 11942
      pageStart: 11937
      title: Proc Natl Acad Sci U S A
      volumeNumber: 106
    title: Design of therapeutic proteins with enhanced stability
  - type: Article
    id: pcbi-1007207-ref014
    authors:
      - type: Person
        familyNames:
          - Jain
        givenNames:
          - T
      - type: Person
        familyNames:
          - Sun
        givenNames:
          - T
      - type: Person
        familyNames:
          - Durand
        givenNames:
          - S
      - type: Person
        familyNames:
          - Hall
        givenNames:
          - A
      - type: Person
        familyNames:
          - Houston
        givenNames:
          - NR
      - type: Person
        familyNames:
          - Nett
        givenNames:
          - JH
    datePublished: '2017'
    isPartOf:
      type: PublicationVolume
      pageEnd: 949
      pageStart: 944
      title: Proc Natl Acad Sci U S A
      volumeNumber: 114
    title: Biophysical properties of the clinical-stage antibody landscape
  - type: Article
    id: pcbi-1007207-ref015
    authors:
      - type: Person
        familyNames:
          - Seeliger
        givenNames:
          - D
      - type: Person
        familyNames:
          - Schulz
        givenNames:
          - P
      - type: Person
        familyNames:
          - Litzenburger
        givenNames:
          - T
      - type: Person
        familyNames:
          - Spitz
        givenNames:
          - J
      - type: Person
        familyNames:
          - Hoerer
        givenNames:
          - S
      - type: Person
        familyNames:
          - Blech
        givenNames:
          - M
    datePublished: '2015'
    isPartOf:
      type: PublicationVolume
      pageEnd: 515
      pageStart: 505
      title: MAbs
      volumeNumber: 7
    title: Boosting antibody developability through rational sequence optimization
  - type: Article
    id: pcbi-1007207-ref016
    authors:
      - type: Person
        familyNames:
          - Dudgeon
        givenNames:
          - K
      - type: Person
        familyNames:
          - Rouet
        givenNames:
          - R
      - type: Person
        familyNames:
          - Kokmeijer
        givenNames:
          - I
      - type: Person
        familyNames:
          - Schofield
        givenNames:
          - P
      - type: Person
        familyNames:
          - Stolp
        givenNames:
          - J
      - type: Person
        familyNames:
          - Langley
        givenNames:
          - D
    datePublished: '2012'
    isPartOf:
      type: PublicationVolume
      pageEnd: 10884
      pageStart: 10879
      title: Proc Natl Acad Sci U S A
      volumeNumber: 109
    title: >-
      General strategy for the generation of human antibody variable domains
      with increased aggregation resistance
  - type: Article
    id: pcbi-1007207-ref017
    authors:
      - type: Person
        familyNames:
          - Miklos
        givenNames:
          - AE
      - type: Person
        familyNames:
          - Kluwe
        givenNames:
          - C
      - type: Person
        familyNames:
          - Der
        givenNames:
          - BS
      - type: Person
        familyNames:
          - Pai
        givenNames:
          - S
      - type: Person
        familyNames:
          - Sircar
        givenNames:
          - A
      - type: Person
        familyNames:
          - Hughes
        givenNames:
          - R
          - a.
    datePublished: '2012'
    isPartOf:
      type: PublicationVolume
      pageEnd: 455
      pageStart: 449
      title: Chem Biol
      volumeNumber: 19
    title: 'Structure-based design of supercharged, highly thermoresistant antibodies'
  - type: Article
    id: pcbi-1007207-ref018
    authors:
      - type: Person
        familyNames:
          - Jespers
        givenNames:
          - L
      - type: Person
        familyNames:
          - Schon
        givenNames:
          - O
      - type: Person
        familyNames:
          - Famm
        givenNames:
          - K
      - type: Person
        familyNames:
          - Winter
        givenNames:
          - G
    datePublished: '2004'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1165
      pageStart: 1161
      title: Nat Biotechnol
      volumeNumber: 22
    title: >-
      Aggregation-resistant domain antibodies selected on phage by heat
      denaturation
  - type: Article
    id: pcbi-1007207-ref019
    authors:
      - type: Person
        familyNames:
          - Cauerhff
        givenNames:
          - A
      - type: Person
        familyNames:
          - Goldbaum
        givenNames:
          - FA
      - type: Person
        familyNames:
          - Braden
        givenNames:
          - BC
    datePublished: '2004'
    isPartOf:
      type: PublicationVolume
      pageEnd: 3544
      pageStart: 3539
      title: Proc Natl Acad Sci U S A
      volumeNumber: 101
    title: Structural mechanism for affinity maturation of an anti-lysozyme antibody
  - type: Article
    id: pcbi-1007207-ref020
    authors:
      - type: Person
        familyNames:
          - Goldenzweig
        givenNames:
          - A
      - type: Person
        familyNames:
          - Goldsmith
        givenNames:
          - M
      - type: Person
        familyNames:
          - Hill
        givenNames:
          - SE
      - type: Person
        familyNames:
          - Gertman
        givenNames:
          - O
      - type: Person
        familyNames:
          - Laurino
        givenNames:
          - P
      - type: Person
        familyNames:
          - Ashani
        givenNames:
          - 'Y'
    datePublished: '2016'
    isPartOf:
      type: PublicationVolume
      pageEnd: 346
      pageStart: 337
      title: Mol Cell
      volumeNumber: 63
    title: >-
      Automated Structure-and Sequence-Based Design of Proteins for High
      Bacterial Expression and Stability
  - type: Article
    id: pcbi-1007207-ref021
    authors:
      - type: Person
        familyNames:
          - Goldenzweig
        givenNames:
          - A
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
    datePublished: '2018'
    isPartOf:
      type: PublicationVolume
      pageEnd: 129
      pageStart: 105
      title: Annu Rev Biochem
      volumeNumber: 87
    title: >-
      Principles of Protein Stability and Their Application in Computational
      Design
  - type: Article
    id: pcbi-1007207-ref022
    authors:
      - type: Person
        familyNames:
          - Campeotto
        givenNames:
          - I
      - type: Person
        familyNames:
          - Goldenzweig
        givenNames:
          - A
      - type: Person
        familyNames:
          - Davey
        givenNames:
          - J
      - type: Person
        familyNames:
          - Barfod
        givenNames:
          - L
      - type: Person
        familyNames:
          - Marshall
        givenNames:
          - JM
      - type: Person
        familyNames:
          - Silk
        givenNames:
          - SE
    datePublished: '2017'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1002
      pageStart: 998
      title: Proc Natl Acad Sci U S A
      volumeNumber: 114
    title: >-
      One-step design of a stable variant of the malaria invasion protein RH5
      for use as a vaccine immunogen
  - type: Article
    id: pcbi-1007207-ref023
    authors:
      - type: Person
        familyNames:
          - Borgo
        givenNames:
          - B
      - type: Person
        familyNames:
          - Havranek
        givenNames:
          - JJ
    datePublished: '2012'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1499
      pageStart: 1494
      title: Proceedings of the National Academy of Sciences
    title: >-
      Automated selection of stabilizing mutations in designed and natural
      proteins
  - type: Article
    id: pcbi-1007207-ref024
    authors:
      - type: Person
        familyNames:
          - Whitehead
        givenNames:
          - TA
      - type: Person
        familyNames:
          - Chevalier
        givenNames:
          - A
      - type: Person
        familyNames:
          - Song
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Dreyfus
        givenNames:
          - C
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
      - type: Person
        familyNames:
          - De
          - Mattos
        givenNames:
          - C
    datePublished: '2012'
    isPartOf:
      type: PublicationVolume
      pageEnd: 548
      pageStart: 543
      title: Nat Biotechnol
      volumeNumber: 30
    title: >-
      Optimization of affinity, specificity and function of designed influenza
      inhibitors using deep sequencing
  - type: Article
    id: pcbi-1007207-ref025
    authors:
      - type: Person
        familyNames:
          - Fowler
        givenNames:
          - DM
      - type: Person
        familyNames:
          - Fields
        givenNames:
          - S
    datePublished: '2014'
    isPartOf:
      type: PublicationVolume
      pageEnd: 807
      pageStart: 801
      title: Nat Methods
      volumeNumber: 11
    title: 'Deep mutational scanning: a new style of protein science'
  - type: Article
    id: pcbi-1007207-ref026
    authors:
      - type: Person
        familyNames:
          - Fowler
        givenNames:
          - DM
      - type: Person
        familyNames:
          - Araya
        givenNames:
          - CL
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
      - type: Person
        familyNames:
          - Kellogg
        givenNames:
          - EH
      - type: Person
        familyNames:
          - Stephany
        givenNames:
          - JJ
      - type: Person
        familyNames:
          - Baker
        givenNames:
          - D
    datePublished: '2010'
    isPartOf:
      type: PublicationVolume
      pageEnd: 746
      pageStart: 741
      title: Nat Methods
      volumeNumber: 7
    title: High-resolution mapping of protein sequence-function relationships
  - type: Article
    id: pcbi-1007207-ref027
    authors:
      - type: Person
        familyNames:
          - Koenig
        givenNames:
          - P
      - type: Person
        familyNames:
          - Lee
        givenNames:
          - CV
      - type: Person
        familyNames:
          - Walters
        givenNames:
          - BT
      - type: Person
        familyNames:
          - Janakiraman
        givenNames:
          - V
      - type: Person
        familyNames:
          - Stinson
        givenNames:
          - J
      - type: Person
        familyNames:
          - Patapoff
        givenNames:
          - TW
    datePublished: '2017'
    isPartOf:
      type: PublicationVolume
      title: Proc Natl Acad Sci U S A
      volumeNumber: 114
    title: >-
      Mutational landscape of antibody variable domains reveals a switch
      modulating the interdomain conformational dynamics and antigen binding
  - type: Article
    id: pcbi-1007207-ref028
    authors:
      - type: Person
        familyNames:
          - Forsyth
        givenNames:
          - CM
      - type: Person
        familyNames:
          - Juan
        givenNames:
          - V
      - type: Person
        familyNames:
          - Akamatsu
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - DuBridge
        givenNames:
          - RB
      - type: Person
        familyNames:
          - Doan
        givenNames:
          - M
      - type: Person
        familyNames:
          - Ivanov
        givenNames:
          - AV
    datePublished: '2013'
    isPartOf:
      type: PublicationVolume
      pageEnd: 532
      pageStart: 523
      title: MAbs
      volumeNumber: 5
    title: >-
      Deep mutational scanning of an antibody against epidermal growth factor
      receptor using mammalian cell display and massively parallel
      pyrosequencing
  - type: Article
    id: pcbi-1007207-ref029
    authors:
      - type: Person
        familyNames:
          - Fujino
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Fujita
        givenNames:
          - R
      - type: Person
        familyNames:
          - Wada
        givenNames:
          - K
      - type: Person
        familyNames:
          - Fujishige
        givenNames:
          - K
      - type: Person
        familyNames:
          - Kanamori
        givenNames:
          - T
      - type: Person
        familyNames:
          - Hunt
        givenNames:
          - L
    datePublished: '2012'
    isPartOf:
      type: PublicationVolume
      pageEnd: 400
      pageStart: 395
      title: Biochem Biophys Res Commun
      volumeNumber: 428
    title: >-
      Robust in vitro affinity maturation strategy based on interface-focused
      high-throughput mutational scanning
  - type: Article
    id: pcbi-1007207-ref030
    authors:
      - type: Person
        familyNames:
          - Adams
        givenNames:
          - RM
      - type: Person
        familyNames:
          - Mora
        givenNames:
          - T
      - type: Person
        familyNames:
          - Walczak
        givenNames:
          - AM
      - type: Person
        familyNames:
          - Kinney
        givenNames:
          - JB
    datePublished: '2016'
    isPartOf:
      type: PublicationVolume
      title: Elife
      volumeNumber: 5
    title: >-
      Measuring the sequence-affinity landscape of antibodies with massively
      parallel titration curves
  - type: Article
    id: pcbi-1007207-ref031
    authors:
      - type: Person
        familyNames:
          - Leung
        givenNames:
          - I
      - type: Person
        familyNames:
          - Dekel
        givenNames:
          - A
      - type: Person
        familyNames:
          - Shifman
        givenNames:
          - JM
      - type: Person
        familyNames:
          - Sidhu
        givenNames:
          - SS
    datePublished: '2016'
    isPartOf:
      type: PublicationVolume
      pageEnd: 8710
      pageStart: 8705
      title: Proc Natl Acad Sci U S A
      volumeNumber: 113
    title: >-
      Saturation scanning of ubiquitin variants reveals a common hot spot for
      binding to USP2 and USP21
  - type: Article
    id: pcbi-1007207-ref032
    authors:
      - type: Person
        familyNames:
          - Whitehead
        givenNames:
          - TA
      - type: Person
        familyNames:
          - Baker
        givenNames:
          - D
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
    datePublished: '2013'
    isPartOf:
      type: PublicationVolume
      pageEnd: 19
      pageStart: 1
      title: Methods Enzymol
      volumeNumber: 523
    title: >-
      Computational design of novel protein binders and experimental affinity
      maturation
  - type: Article
    id: pcbi-1007207-ref033
    authors:
      - type: Person
        familyNames:
          - Braden
        givenNames:
          - BC
      - type: Person
        familyNames:
          - Souchon
        givenNames:
          - H
      - type: Person
        familyNames:
          - Eiselé
        givenNames:
          - JL
      - type: Person
        familyNames:
          - Bentley
        givenNames:
          - GA
      - type: Person
        familyNames:
          - Bhat
        givenNames:
          - TN
      - type: Person
        familyNames:
          - Navaza
        givenNames:
          - J
    datePublished: '1994'
    isPartOf:
      type: PublicationVolume
      pageEnd: 781
      pageStart: 767
      title: J Mol Biol
      volumeNumber: 243
    title: >-
      Three-dimensional structures of the free and the antigen-complexed Fab
      from monoclonal anti-lysozyme antibody D44.1
  - type: Article
    id: pcbi-1007207-ref034
    authors:
      - type: Person
        familyNames:
          - Colman
        givenNames:
          - PM
    datePublished: '1988'
    isPartOf:
      type: PublicationVolume
      pageEnd: 132
      pageStart: 99
      title: Adv Immunol
      volumeNumber: 43
    title: >-
      Structure of antibody-antigen complexes: implications for immune
      recognition
  - type: Article
    id: pcbi-1007207-ref035
    authors:
      - type: Person
        familyNames:
          - Zimmermann
        givenNames:
          - J
      - type: Person
        familyNames:
          - Oakman
        givenNames:
          - EL
      - type: Person
        familyNames:
          - Thorpe
        givenNames:
          - IF
      - type: Person
        familyNames:
          - Shi
        givenNames:
          - X
      - type: Person
        familyNames:
          - Abbyad
        givenNames:
          - P
      - type: Person
        familyNames:
          - Brooks
        givenNames:
          - CL
    datePublished: '2006'
    isPartOf:
      type: PublicationVolume
      pageEnd: 13727
      pageStart: 13722
      title: Proceedings of the National Academy of Sciences
      volumeNumber: 103
    title: >-
      Antibody evolution constrains conformational heterogeneity by tailoring
      protein dynamics
  - type: Article
    id: pcbi-1007207-ref036
    authors:
      - type: Person
        familyNames:
          - Clark
        givenNames:
          - LA
      - type: Person
        familyNames:
          - Ganesan
        givenNames:
          - S
      - type: Person
        familyNames:
          - Papp
        givenNames:
          - S
      - type: Person
        familyNames:
          - van
          - Vlijmen
        givenNames:
          - HWT
    datePublished: '2006'
    isPartOf:
      type: PublicationVolume
      pageEnd: 340
      pageStart: 333
      title: J Immunol
      volumeNumber: 177
    title: >-
      Trends in antibody sequence changes during the somatic hypermutation
      process
  - type: Article
    id: pcbi-1007207-ref037
    authors:
      - type: Person
        familyNames:
          - Adair
        givenNames:
          - JR
      - type: Person
        familyNames:
          - Athwal
        givenNames:
          - DS
      - type: Person
        familyNames:
          - Emtage
        givenNames:
          - JS
    datePublished: '1995'
    isPartOf:
      type: PublicationVolume
      title: European Patent
      volumeNumber: 460167
    title: Humanised antibodies
  - type: Article
    id: pcbi-1007207-ref038
    authors:
      - type: Person
        familyNames:
          - Lapidoth
        givenNames:
          - GD
      - type: Person
        familyNames:
          - Baran
        givenNames:
          - D
      - type: Person
        familyNames:
          - Pszolla
        givenNames:
          - GM
      - type: Person
        familyNames:
          - Norn
        givenNames:
          - C
      - type: Person
        familyNames:
          - Alon
        givenNames:
          - A
      - type: Person
        familyNames:
          - Tyka
        givenNames:
          - MD
    datePublished: '2015'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1406
      pageStart: 1385
      title: Proteins
      volumeNumber: 83
    title: >-
      AbDesign: An algorithm for combinatorial backbone design guided by natural
      conformations and sequences
  - type: Article
    id: pcbi-1007207-ref039
    authors:
      - type: Person
        familyNames:
          - Baran
        givenNames:
          - D
      - type: Person
        familyNames:
          - Pszolla
        givenNames:
          - MG
      - type: Person
        familyNames:
          - Lapidoth
        givenNames:
          - GD
      - type: Person
        familyNames:
          - Norn
        givenNames:
          - C
      - type: Person
        familyNames:
          - Dym
        givenNames:
          - O
      - type: Person
        familyNames:
          - Unger
        givenNames:
          - T
    datePublished: '2017'
    isPartOf:
      type: PublicationVolume
      pageEnd: 10905
      pageStart: 10900
      title: Proc Natl Acad Sci U S A
      volumeNumber: 114
    title: Principles for computational design of binding antibodies
  - type: Article
    id: pcbi-1007207-ref040
    authors:
      - type: Person
        familyNames:
          - Lapidoth
        givenNames:
          - G
      - type: Person
        familyNames:
          - Khersonsky
        givenNames:
          - O
      - type: Person
        familyNames:
          - Lipsh
        givenNames:
          - R
      - type: Person
        familyNames:
          - Dym
        givenNames:
          - O
      - type: Person
        familyNames:
          - Albeck
        givenNames:
          - S
      - type: Person
        familyNames:
          - Rogotner
        givenNames:
          - S
    datePublished: '2018'
    isPartOf:
      type: PublicationVolume
      pageStart: 2780
      title: Nat Commun
      volumeNumber: 9
    title: >-
      Highly active enzymes by automated combinatorial backbone assembly and
      sequence design
  - type: Article
    id: pcbi-1007207-ref041
    authors:
      - type: Person
        familyNames:
          - Khersonsky
        givenNames:
          - O
      - type: Person
        familyNames:
          - Lipsh
        givenNames:
          - R
      - type: Person
        familyNames:
          - Avizemer
        givenNames:
          - Z
      - type: Person
        familyNames:
          - Ashani
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Goldsmith
        givenNames:
          - M
      - type: Person
        familyNames:
          - Leader
        givenNames:
          - H
    datePublished: '2018'
    isPartOf:
      type: PublicationVolume
      pageEnd: 186
      pageStart: 178
      title: Mol Cell
      volumeNumber: 72
    title: Automated Design of Efficient and Functionally Diverse Enzyme Repertoires
  - type: Article
    id: pcbi-1007207-ref042
    authors:
      - type: Person
        familyNames:
          - Netzer
        givenNames:
          - R
      - type: Person
        familyNames:
          - Listov
        givenNames:
          - D
      - type: Person
        familyNames:
          - Lipsh
        givenNames:
          - R
      - type: Person
        familyNames:
          - Dym
        givenNames:
          - O
      - type: Person
        familyNames:
          - Albeck
        givenNames:
          - S
      - type: Person
        familyNames:
          - Knop
        givenNames:
          - O
    datePublished: '2018'
    isPartOf:
      type: PublicationVolume
      pageStart: 5286
      title: Nat Commun
      volumeNumber: 9
    title: >-
      Ultrahigh specificity in a network of computationally designed
      protein-interaction pairs
  - type: Article
    id: pcbi-1007207-ref043
    authors:
      - type: Person
        familyNames:
          - Khersonsky
        givenNames:
          - O
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
    datePublished: '2016'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1187
      pageStart: 1179
      title: Protein Sci
      volumeNumber: 25
    title: Why reinvent the wheel? Building new proteins based on ready-made parts
  - type: Article
    id: pcbi-1007207-ref044
    authors:
      - type: Person
        familyNames:
          - Abhinandan
        givenNames:
          - KR
      - type: Person
        familyNames:
          - Martin
        givenNames:
          - ACR
    datePublished: '2010'
    isPartOf:
      type: PublicationVolume
      pageEnd: 697
      pageStart: 689
      title: Protein Eng Des Sel
      volumeNumber: 23
    title: Analysis and prediction of VH/VL packing in antibodies
  - type: Article
    id: pcbi-1007207-ref045
    authors:
      - type: Person
        familyNames:
          - Fuh
        givenNames:
          - G
      - type: Person
        familyNames:
          - Wu
        givenNames:
          - P
      - type: Person
        familyNames:
          - Liang
        givenNames:
          - W-C
      - type: Person
        familyNames:
          - Ultsch
        givenNames:
          - M
      - type: Person
        familyNames:
          - Lee
        givenNames:
          - CV
      - type: Person
        familyNames:
          - Moffat
        givenNames:
          - B
    datePublished: '2006'
    isPartOf:
      type: PublicationVolume
      pageEnd: 6631
      pageStart: 6625
      title: J Biol Chem
      volumeNumber: 281
    title: >-
      Structure-Function Studies of Two Synthetic Anti-vascular Endothelial
      Growth Factor Fabs and Comparison with the Avastin Fab
  - type: Article
    id: pcbi-1007207-ref046
    authors:
      - type: Person
        familyNames:
          - Song
        givenNames:
          - H
      - type: Person
        familyNames:
          - Zhang
        givenNames:
          - B
      - type: Person
        familyNames:
          - Watson
        givenNames:
          - MA
      - type: Person
        familyNames:
          - Humphrey
        givenNames:
          - PA
      - type: Person
        familyNames:
          - Lim
        givenNames:
          - H
      - type: Person
        familyNames:
          - Milbrandt
        givenNames:
          - J
    datePublished: '2009'
    isPartOf:
      type: PublicationVolume
      pageEnd: 3319
      pageStart: 3307
      title: Oncogene
      volumeNumber: 28
    title: >-
      Loss of Nkx3.1 leads to the activation of discrete downstream target genes
      during prostate tumorigenesis
  - type: Article
    id: pcbi-1007207-ref047
    authors:
      - type: Person
        familyNames:
          - Grossman
        givenNames:
          - I
      - type: Person
        familyNames:
          - Alon
        givenNames:
          - A
      - type: Person
        familyNames:
          - Ilani
        givenNames:
          - T
      - type: Person
        familyNames:
          - Fass
        givenNames:
          - D
    datePublished: '2013'
    isPartOf:
      type: PublicationVolume
      pageEnd: 4378
      pageStart: 4366
      title: J Mol Biol
      volumeNumber: 425
    title: >-
      An inhibitory antibody blocks the first step in the dithiol/disulfide
      relay mechanism of the enzyme QSOX1
  - type: Article
    id: pcbi-1007207-ref048
    authors:
      - type: Person
        familyNames:
          - Alon
        givenNames:
          - A
      - type: Person
        familyNames:
          - Grossman
        givenNames:
          - I
      - type: Person
        familyNames:
          - Gat
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Kodali
        givenNames:
          - VK
      - type: Person
        familyNames:
          - DiMaio
        givenNames:
          - F
      - type: Person
        familyNames:
          - Mehlman
        givenNames:
          - T
    datePublished: '2012'
    isPartOf:
      type: PublicationVolume
      pageEnd: 418
      pageStart: 414
      title: Nature
      volumeNumber: 488
    title: The dynamic disulphide relay of quiescin sulphydryl oxidase
  - type: Article
    id: pcbi-1007207-ref049
    authors:
      - type: Person
        familyNames:
          - Lee
        givenNames:
          - CV
      - type: Person
        familyNames:
          - Liang
        givenNames:
          - W-C
      - type: Person
        familyNames:
          - Dennis
        givenNames:
          - MS
      - type: Person
        familyNames:
          - Eigenbrot
        givenNames:
          - C
      - type: Person
        familyNames:
          - Sidhu
        givenNames:
          - SS
      - type: Person
        familyNames:
          - Fuh
        givenNames:
          - G
    datePublished: '2004'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1093
      pageStart: 1073
      title: J Mol Biol
      volumeNumber: 340
    title: >-
      High-affinity human antibodies from phage-displayed synthetic Fab
      libraries with a single framework scaffold
  - type: Article
    id: pcbi-1007207-ref050
    authors:
      - type: Person
        familyNames:
          - Kellogg
        givenNames:
          - EH
      - type: Person
        familyNames:
          - Leaver-Fay
        givenNames:
          - A
      - type: Person
        familyNames:
          - Baker
        givenNames:
          - D
    datePublished: '2011'
    isPartOf:
      type: PublicationVolume
      pageEnd: 838
      pageStart: 830
      title: Proteins
      volumeNumber: 79
    title: >-
      Role of conformational sampling in computing mutation-induced changes in
      protein structure and stability
  - type: Article
    id: pcbi-1007207-ref051
    authors:
      - type: Person
        familyNames:
          - Yin
        givenNames:
          - S
      - type: Person
        familyNames:
          - Ding
        givenNames:
          - F
      - type: Person
        familyNames:
          - Dokholyan
        givenNames:
          - NV
    datePublished: '2007'
    isPartOf:
      type: PublicationVolume
      pageEnd: 467
      pageStart: 466
      title: Nat Methods
      volumeNumber: 4
    title: 'Eris: an automated estimator of protein stability'
  - type: Article
    id: pcbi-1007207-ref052
    authors:
      - type: Person
        familyNames:
          - Jarasch
        givenNames:
          - A
      - type: Person
        familyNames:
          - Koll
        givenNames:
          - H
      - type: Person
        familyNames:
          - Regula
        givenNames:
          - JT
      - type: Person
        familyNames:
          - Bader
        givenNames:
          - M
      - type: Person
        familyNames:
          - Papadimitriou
        givenNames:
          - A
      - type: Person
        familyNames:
          - Kettenberger
        givenNames:
          - H
    datePublished: '2015'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1898
      pageStart: 1885
      title: J Pharm Sci
      volumeNumber: 104
    title: >-
      Developability assessment during the selection of novel therapeutic
      antibodies
  - type: Article
    id: pcbi-1007207-ref053
    authors:
      - type: Person
        familyNames:
          - Boyken
        givenNames:
          - SE
      - type: Person
        familyNames:
          - Chen
        givenNames:
          - Z
      - type: Person
        familyNames:
          - Groves
        givenNames:
          - B
      - type: Person
        familyNames:
          - Langan
        givenNames:
          - RA
      - type: Person
        familyNames:
          - Oberdorfer
        givenNames:
          - G
      - type: Person
        familyNames:
          - Ford
        givenNames:
          - A
    datePublished: '2016'
    isPartOf:
      type: PublicationVolume
      pageEnd: 687
      pageStart: 680
      title: Science
      volumeNumber: 352
    title: >-
      De novo design of protein homo-oligomers with modular hydrogen-bond
      network-mediated specificity
  - type: Article
    id: pcbi-1007207-ref054
    authors:
      - type: Person
        familyNames:
          - Netzer
        givenNames:
          - R
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
    datePublished: '2016'
    isPartOf:
      type: PublicationVolume
      pageEnd: 658
      pageStart: 657
      title: Science
      volumeNumber: 352
    title: >-
      Inspired by nature: designed proteins have structural features resembling
      those of natural active sites
  - type: Article
    id: pcbi-1007207-ref055
    authors:
      - type: Person
        familyNames:
          - Ben-Nissan
        givenNames:
          - G
      - type: Person
        familyNames:
          - Vimer
        givenNames:
          - S
      - type: Person
        familyNames:
          - Warszawski
        givenNames:
          - S
      - type: Person
        familyNames:
          - Katz
        givenNames:
          - A
      - type: Person
        familyNames:
          - Yona
        givenNames:
          - M
      - type: Person
        familyNames:
          - Unger
        givenNames:
          - T
    isPartOf:
      type: PublicationVolume
      title: Rapid Characterization of Secreted Recombinant Proteins
    title: ''
  - type: Article
    id: pcbi-1007207-ref056
    authors:
      - type: Person
        familyNames:
          - Israel
        givenNames:
          - BA
      - type: Person
        familyNames:
          - Jiang
        givenNames:
          - L
      - type: Person
        familyNames:
          - Gannon
        givenNames:
          - SA
      - type: Person
        familyNames:
          - Thorpe
        givenNames:
          - C
    datePublished: '2014'
    isPartOf:
      type: PublicationVolume
      pageEnd: 135
      pageStart: 129
      title: Free Radic Biol Med
      volumeNumber: 69
    title: >-
      Disulfide bond generation in mammalian blood serum: detection and
      purification of quiescin-sulfhydryl oxidase
  - type: Article
    id: pcbi-1007207-ref057
    authors:
      - type: Person
        familyNames:
          - Chailyan
        givenNames:
          - A
      - type: Person
        familyNames:
          - Marcatili
        givenNames:
          - P
      - type: Person
        familyNames:
          - Tramontano
        givenNames:
          - A
    datePublished: '2011'
    isPartOf:
      type: PublicationVolume
      pageEnd: 2866
      pageStart: 2858
      title: FEBS J
      volumeNumber: 278
    title: >-
      The association of heavy and light chain variable domains in antibodies:
      implications for antigen specificity
  - type: Article
    id: pcbi-1007207-ref058
    authors:
      - type: Person
        familyNames:
          - Almagro
        givenNames:
          - JC
      - type: Person
        familyNames:
          - Teplyakov
        givenNames:
          - A
      - type: Person
        familyNames:
          - Luo
        givenNames:
          - J
      - type: Person
        familyNames:
          - Sweet
        givenNames:
          - RW
      - type: Person
        familyNames:
          - Kodangattil
        givenNames:
          - S
      - type: Person
        familyNames:
          - Hernandez-Guzman
        givenNames:
          - F
    datePublished: '2014'
    isPartOf:
      type: PublicationVolume
      pageEnd: 1562
      pageStart: 1553
      title: 'Proteins: Struct Funct Bioinf'
      volumeNumber: 82
    title: Second antibody modeling assessment (AMA-II)
  - type: Article
    id: pcbi-1007207-ref059
    authors:
      - type: Person
        familyNames:
          - Norn
        givenNames:
          - CH
      - type: Person
        familyNames:
          - Lapidoth
        givenNames:
          - G
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
    datePublished: '2017'
    isPartOf:
      type: PublicationVolume
      pageEnd: 38
      pageStart: 30
      title: Proteins
      volumeNumber: 85
    title: >-
      High-accuracy modeling of antibody structures by a search for
      minimum-energy recombination of backbone fragments
  - type: Article
    id: pcbi-1007207-ref060
    authors:
      - type: Person
        familyNames:
          - Lapidoth
        givenNames:
          - G
      - type: Person
        familyNames:
          - Parker
        givenNames:
          - J
      - type: Person
        familyNames:
          - Prilusky
        givenNames:
          - J
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
    datePublished: '2019'
    isPartOf:
      type: PublicationIssue
      isPartOf:
        type: PublicationVolume
        title: Bioinformatics
        volumeNumber: 35
      issueNumber: 9
      pageEnd: 1593
      pageStart: 1591
    title: >-
      AbPredict 2: a server for accurate and unstrained structure prediction of
      antibody variable domains
  - type: Article
    id: pcbi-1007207-ref061
    authors:
      - type: Person
        familyNames:
          - Rini
        givenNames:
          - JM
      - type: Person
        familyNames:
          - Schulze-Gahmen
        givenNames:
          - U
      - type: Person
        familyNames:
          - Wilson
        givenNames:
          - IA
    datePublished: '1992'
    isPartOf:
      type: PublicationVolume
      pageEnd: 965
      pageStart: 959
      title: Science
      volumeNumber: 255
    title: >-
      Structural evidence for induced fit as a mechanism for antibody-antigen
      recognition
  - type: Article
    id: pcbi-1007207-ref062
    authors:
      - type: Person
        familyNames:
          - Pauling
        givenNames:
          - L
    datePublished: '1940'
    isPartOf:
      type: PublicationVolume
      pageEnd: 2657
      pageStart: 2643
      title: J Am Chem Soc
      volumeNumber: 62
    title: A theory of the structure and process of formation of antibodies
  - type: Article
    id: pcbi-1007207-ref063
    authors:
      - type: Person
        familyNames:
          - Stanfield
        givenNames:
          - RL
      - type: Person
        familyNames:
          - Takimoto-Kamimura
        givenNames:
          - M
      - type: Person
        familyNames:
          - Rini
        givenNames:
          - JM
      - type: Person
        familyNames:
          - Profy
        givenNames:
          - AT
      - type: Person
        familyNames:
          - Wilson
        givenNames:
          - IA
    datePublished: '1993'
    isPartOf:
      type: PublicationVolume
      pageEnd: 93
      pageStart: 83
      title: Structure
      volumeNumber: 1
    title: Major antigen-induced domain rearrangements in an antibody
  - type: Article
    id: pcbi-1007207-ref064
    authors:
      - type: Person
        familyNames:
          - Elazar
        givenNames:
          - A
      - type: Person
        familyNames:
          - Weinstein
        givenNames:
          - J
      - type: Person
        familyNames:
          - Biran
        givenNames:
          - I
      - type: Person
        familyNames:
          - Fridman
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Bibi
        givenNames:
          - E
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
    datePublished: '2016'
    isPartOf:
      type: PublicationVolume
      title: Elife
      volumeNumber: 5
    title: >-
      Mutational scanning reveals the determinants of protein insertion and
      association energetics in the plasma membrane
  - type: Article
    id: pcbi-1007207-ref065
    authors:
      - type: Person
        familyNames:
          - Liu
        givenNames:
          - H
      - type: Person
        familyNames:
          - Naismith
        givenNames:
          - JH
    datePublished: '2008'
    isPartOf:
      type: PublicationVolume
      pageStart: 91
      title: BMC Biotechnol
      volumeNumber: 8
    title: >-
      An efficient one-step site-directed deletion, insertion, single and
      multiple-site plasmid mutagenesis protocol
  - type: Article
    id: pcbi-1007207-ref066
    authors:
      - type: Person
        familyNames:
          - Gietz
        givenNames:
          - RD
      - type: Person
        familyNames:
          - Schiestl
        givenNames:
          - RH
    datePublished: '2007'
    isPartOf:
      type: PublicationVolume
      pageEnd: 4
      pageStart: 1
      title: Nat Protoc
      volumeNumber: 2
    title: >-
      Frozen competent yeast cells that can be transformed with high efficiency
      using the LiAc/SS carrier DNA/PEG method
  - type: Article
    id: pcbi-1007207-ref067
    authors:
      - type: Person
        familyNames:
          - Fleishman
        givenNames:
          - SJ
      - type: Person
        familyNames:
          - Leaver-Fay
        givenNames:
          - A
      - type: Person
        familyNames:
          - Corn
        givenNames:
          - JE
      - type: Person
        familyNames:
          - Strauch
        givenNames:
          - E-M
      - type: Person
        familyNames:
          - Khare
        givenNames:
          - SD
      - type: Person
        familyNames:
          - Koga
        givenNames:
          - 'N'
    datePublished: '2011'
    isPartOf:
      type: PublicationVolume
      title: PLoS One
      volumeNumber: 6
    title: >-
      RosettaScripts: a scripting language interface to the Rosetta
      macromolecular modeling suite
  - type: Article
    id: pcbi-1007207-ref068
    authors:
      - type: Person
        familyNames:
          - O’Meara
        givenNames:
          - MJ
      - type: Person
        familyNames:
          - Leaver-Fay
        givenNames:
          - A
      - type: Person
        familyNames:
          - Tyka
        givenNames:
          - MD
      - type: Person
        familyNames:
          - Stein
        givenNames:
          - A
      - type: Person
        familyNames:
          - Houlihan
        givenNames:
          - K
      - type: Person
        familyNames:
          - DiMaio
        givenNames:
          - F
    datePublished: '2015'
    isPartOf:
      type: PublicationVolume
      pageEnd: 622
      pageStart: 609
      title: J Chem Theory Comput
      volumeNumber: 11
    title: >-
      Combined covalent-electrostatic model of hydrogen bonding improves
      structure prediction with Rosetta
  - type: Article
    id: pcbi-1007207-ref069
    authors:
      - type: Person
        familyNames:
          - Park
        givenNames:
          - H
      - type: Person
        familyNames:
          - Bradley
        givenNames:
          - P
      - type: Person
        familyNames:
          - Greisen
        givenNames:
          - P
        honorificSuffix: Jr
      - type: Person
        familyNames:
          - Liu
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Mulligan
        givenNames:
          - VK
      - type: Person
        familyNames:
          - Kim
        givenNames:
          - DE
    datePublished: '2016'
    isPartOf:
      type: PublicationVolume
      pageEnd: 6212
      pageStart: 6201
      title: J Chem Theory Comput
      volumeNumber: 12
    title: >-
      Simultaneous Optimization of Biomolecular Energy Functions on Features
      from Small Molecules and Macromolecules
  - type: Article
    id: pcbi-1007207-ref070
    authors:
      - type: Person
        familyNames:
          - Ben-Nissan
        givenNames:
          - G
      - type: Person
        familyNames:
          - Belov
        givenNames:
          - ME
      - type: Person
        familyNames:
          - Morgenstern
        givenNames:
          - D
      - type: Person
        familyNames:
          - Levin
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Dym
        givenNames:
          - O
      - type: Person
        familyNames:
          - Arkind
        givenNames:
          - G
    datePublished: '2017'
    isPartOf:
      type: PublicationVolume
      pageEnd: 4715
      pageStart: 4708
      title: Anal Chem
      volumeNumber: 89
    title: >-
      Triple-Stage Mass Spectrometry Unravels the Heterogeneity of an Endogenous
      Protein Complex
  - type: Article
    id: pcbi-1007207-ref071
    authors:
      - type: Person
        familyNames:
          - Kirshenbaum
        givenNames:
          - 'N'
      - type: Person
        familyNames:
          - Michaelevski
        givenNames:
          - I
      - type: Person
        familyNames:
          - Sharon
        givenNames:
          - M
    datePublished: '2010'
    isPartOf:
      type: PublicationVolume
      title: J Vis Exp
    title: Analyzing large protein complexes by structural mass spectrometry
  - type: Article
    id: pcbi-1007207-ref072
    authors:
      - type: Person
        familyNames:
          - Tiller
        givenNames:
          - T
      - type: Person
        familyNames:
          - Meffre
        givenNames:
          - E
      - type: Person
        familyNames:
          - Yurasov
        givenNames:
          - S
      - type: Person
        familyNames:
          - Tsuiji
        givenNames:
          - M
      - type: Person
        familyNames:
          - Nussenzweig
        givenNames:
          - MC
      - type: Person
        familyNames:
          - Wardemann
        givenNames:
          - H
    datePublished: '2008'
    isPartOf:
      type: PublicationVolume
      pageEnd: 124
      pageStart: 112
      title: J Immunol Methods
      volumeNumber: 329
    title: >-
      Efficient generation of monoclonal antibodies from single human B cells by
      single cell RT-PCR and expression vector cloning
  - type: Article
    id: pcbi-1007207-ref073
    authors:
      - type: Person
        familyNames:
          - Unger
        givenNames:
          - T
      - type: Person
        familyNames:
          - Jacobovitch
        givenNames:
          - 'Y'
      - type: Person
        familyNames:
          - Dantes
        givenNames:
          - A
      - type: Person
        familyNames:
          - Bernheim
        givenNames:
          - R
      - type: Person
        familyNames:
          - Peleg
        givenNames:
          - 'Y'
    datePublished: '2010'
    isPartOf:
      type: PublicationVolume
      pageEnd: 44
      pageStart: 34
      title: J Struct Biol
      volumeNumber: 172
    title: >-
      Applications of the Restriction Free (RF) cloning procedure for molecular
      manipulations and protein expression
title: >-
  Optimizing antibody affinity and stability by the automated design of the
  variable light-heavy chain interfaces
meta:
  authorNotes:
    - The authors have declared that no competing interests exist.
content:
  - type: Heading
    id: sec001
    depth: 1
    content:
      - Introduction
  - type: Paragraph
    content:
      - >-
        High-affinity natural antibodies are generated through an iterative
        process of mutation and selection for antigen binding known as affinity
        maturation. Affinity maturation also selects antibodies that exhibit
        higher stability and expressibility [
      - type: Cite
        target: pcbi-1007207-ref001
        content:
          - '1'
      - >-
        ], both of which are essential parameters in the development of
        antibodies into research or medical tools [
      - type: Cite
        target: pcbi-1007207-ref002
        content:
          - '2'
      - >-
        ]. In recent decades, synthetic antibody repertoires have been widely
        adopted in antibody discovery and optimization, providing greater
        control over the selection process than animal immunization. In this
        approach, a library of antibody variable fragments (Fv) is displayed,
        for instance on yeast cells, and screened to select high-affinity
        binders or to improve the affinity of existing antibodies [
      - type: Cite
        target: pcbi-1007207-ref003
        content:
          - '3'
      - ']. These methods are powerful ['
      - type: Cite
        target: pcbi-1007207-ref004
        content:
          - '4'
      - ','
      - type: Cite
        target: pcbi-1007207-ref005
        content:
          - '5'
      - >-
        ], but a large fraction of high-affinity antibodies isolated from
        synthetic repertoires exhibits impaired stability [
      - type: Cite
        target: pcbi-1007207-ref006
        content:
          - '6'
      - >-
        ]. Impaired stability can limit expression yields and increase
        aggregation propensity [
      - type: Cite
        target: pcbi-1007207-ref007
        content:
          - '7'
      - '], resulting in high production costs ['
      - type: Cite
        target: pcbi-1007207-ref008
        content:
          - '8'
      - >-
        ], fast antibody clearance from circulation and adverse immune responses
        in patients [
      - type: Cite
        target: pcbi-1007207-ref009
        content:
          - '9'
      - >-
        ]. Thus, the tradeoff between antibody stability (including solubility
        and expressibility) and affinity can delay and even block the
        development of antibodies in research and medicine [
      - type: Cite
        target: pcbi-1007207-ref010
        content:
          - '10'
      - >-
        ]. General methods to improve antibody stability while maintaining or
        even increasing affinity are therefore urgently needed to reduce the
        attrition rate in antibody development pipelines [
      - type: Cite
        target: pcbi-1007207-ref011
        content:
          - '11'
      - '].'
  - type: Paragraph
    content:
      - >-
        To boost antibody stability and affinity, computational design methods
        have been developed. These have focused on the Fv
        complementarity-determining regions (CDRs), which are typically in
        direct contact with the antigen. Some methods, for instance, improved
        electrostatic complementarity with the antigen [
      - type: Cite
        target: pcbi-1007207-ref012
        content:
          - '12'
      - '] or eliminated hydrophobic surface patches ['
      - type: Cite
        target: pcbi-1007207-ref013
        content:
          - '13'
      - –
      - type: Cite
        target: pcbi-1007207-ref018
        content:
          - '18'
      - >-
        ]. Natural and laboratory affinity maturation, by contrast, introduce
        mutations in both the CDRs and the antibody core [
      - type: Cite
        target: pcbi-1007207-ref001
        content:
          - '1'
      - ','
      - type: Cite
        target: pcbi-1007207-ref005
        content:
          - '5'
      - >-
        ]. Core mutations may improve antibody stability by eliminating packing
        defects, and they may enhance affinity by preorganizing the
        antigen-binding site [
      - type: Cite
        target: pcbi-1007207-ref001
        content:
          - '1'
      - >-
        ]. Although mutations in the core may contribute less to affinity than
        ones in the CDRs, they are more likely to retain the intricate structure
        of the antigen-binding site and are therefore likely to be compatible
        with affinity-enhancing mutations in the CDRs that were obtained through
        other optimization strategies. The antibody core, however, is a large
        and densely packed region, complicating the design of improved variants
        [
      - type: Cite
        target: pcbi-1007207-ref005
        content:
          - '5'
      - ','
      - type: Cite
        target: pcbi-1007207-ref019
        content:
          - '19'
      - >-
        ]. For instance, we recently presented and validated an automated
        computational strategy, called PROSS [
      - type: Cite
        target: pcbi-1007207-ref020
        content:
          - '20'
      - >-
        ], for protein-stability design. Similar to other stability design
        algorithms [
      - type: Cite
        target: pcbi-1007207-ref021
        content:
          - '21'
      - >-
        ], however, PROSS only rarely introduces core mutations and does not
        improve binding affinity [
      - type: Cite
        target: pcbi-1007207-ref022
        content:
          - '22'
      - >-
        ]. Reliable prediction of mutational effects in the antibody core and
        especially successful design of networks of interacting multipoint core
        mutations has, therefore, remained a challenge [
      - type: Cite
        target: pcbi-1007207-ref021
        content:
          - '21'
      - ','
      - type: Cite
        target: pcbi-1007207-ref023
        content:
          - '23'
      - '].'
  - type: Paragraph
    content:
      - >-
        Recently, deep mutational scanning has been successfully applied to
        study the mutational tolerance of antibodies and other binders [
      - type: Cite
        target: pcbi-1007207-ref024
        content:
          - '24'
      - –
      - type: Cite
        target: pcbi-1007207-ref030
        content:
          - '30'
      - >-
        ]. In this approach, amino acid positions in the binder are
        systematically mutated to all of the natural amino acid identities; the
        mutants are pooled into one library containing all single-point
        mutations; populations of binders are selected from this library using 
      - type: Emphasis
        content:
          - in vitro
      - ' display and high-throughput screening; and the selected and unselected populations are subjected to deep-sequencing analysis to infer which mutations are enriched relative to the starting binder, thus systematically identifying affinity-enhancing mutations. Deep mutational scanning has been very successfully used to guide protein design and engineering of improved binders ['
      - type: Cite
        target: pcbi-1007207-ref024
        content:
          - '24'
      - ','
      - type: Cite
        target: pcbi-1007207-ref026
        content:
          - '26'
      - ','
      - type: Cite
        target: pcbi-1007207-ref031
        content:
          - '31'
      - ','
      - type: Cite
        target: pcbi-1007207-ref032
        content:
          - '32'
      - >-
        ] but has not yet been exploited to improve protein-design methodology
        itself. The large improvements in the reliability and breadth of
        detection of affinity-enhancing mutations through deep mutational
        scanning inspired us to revisit the challenge of accurately predicting
        the effects of core mutations on antibody affinity and stability. Deep
        mutational scanning guided us in uncovering a cluster of core positions
        at the light-heavy chain (vL-vH) interface where many affinity-enhancing
        mutations occurred. We then used these systematic data to establish
        general rules for computational design of antibody Fvs with improved
        vL-vH interactions; we implemented these rules as an automated method,
        called AbLIFT and made it available through a web server (
      - type: Link
        target: 'http://ablift.weizmann.ac.il/'
        content:
          - 'http://AbLIFT.weizmann.ac.il'
      - >-
        ). AbLIFT designs exhibited striking gains in affinity, stability, and
        expressibility in two unrelated antibodies that target the human disease
        markers Vascular-Epidermal Growth Factor (VEGF) and the enzyme Quiescin
        Sulfhydryl Oxidase 1 (QSOX1).
  - type: Heading
    id: sec002
    depth: 1
    content:
      - Results
  - type: Heading
    id: sec003
    depth: 2
    content:
      - A cluster of affinity-enhancing mutations at the vL-vH interface
  - type: Paragraph
    content:
      - >-
        To study the mutational tolerance of an antibody Fv, we selected 135
        positions in the anti-lysozyme antibody D44.1 [
      - type: Cite
        target: pcbi-1007207-ref033
        content:
          - '33'
      - '] for deep mutational scanning ('
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s001'
            content:
              - S1A Fig
      - >-
        ). The positions encompassed most of the CDRs, the vL-vH interface and
        additional peripheral positions (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g001'
            content:
              - Fig 1A
      - >-
        ). D44.1 and each point mutant were genetically encoded as single-chain
        variable fragments (scFv) in which the heavy chain was fused to the
        light chain via a flexible linker, and the genes were transformed into
        yeast cells for binding and expression screens by yeast display [
      - type: Cite
        target: pcbi-1007207-ref003
        content:
          - '3'
      - >-
        ]. Following incubation with hen egg-white lysozyme, the top 15% binders
        were selected from this library, and the same library was also subjected
        to low-stringency selection for expression levels to provide a baseline.
        The plasmids containing scFv-encoding genes from both selections were
        purified, amplified by PCR, and subjected to deep sequencing, resulting
        in 8 million high-quality reads [
      - type: Cite
        target: pcbi-1007207-ref032
        content:
          - '32'
      - >-
        ]. We then determined the enrichment of each mutant relative to D44.1 as
        the ratio between populations selected for binding and expression (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g001'
            content:
              - Fig 1B
      - ).
  - type: Figure
    id: pcbi.1007207.g001
    caption:
      - type: Heading
        id: sec003
        depth: 2
        content:
          - Deep mutational scanning of an antibody variable fragment (Fv).
      - type: Paragraph
        content:
          - (
          - type: Strong
            content:
              - a
          - >-
            ) 135 positions across the Fv of the anti-lysozyme antibody D44.1
            (encompassing the vL-vH interface and all positions from the
            antigen-binding surface to the level of the disulfide-linked
            cysteines) were individually diversified using degenerate codons
            (NNS) to encode all point mutations. The variants were transformed
            into yeast cells, subjected to low-stringency selection for binding
            (green spots) and for expression (purple + green spots), and then to
            deep-sequencing analysis. (
          - type: Strong
            content:
              - b
          - >-
            ) 34 Fv positions exhibited enhanced binding upon mutation (blue).
            Amino acids (x-axis) are numbered according to ref. [
          - type: Cite
            target: pcbi-1007207-ref033
            content:
              - '33'
          - >-
            ]. Blue, red and gray encode mutations that are enriched, depleted,
            or ones with insufficient data, respectively. Amino acid identities
            in the parental antibody are indicated in one-letter code for each
            position. (
          - type: Strong
            content:
              - c
          - >-
            ) At several positions, more than five alternative identities
            enhanced affinity, indicating that the combinatorial sequence space
            of affinity-enhancing multipoint mutants is large. Positions at the
            vL-vH interface are colored purple. (
          - type: Strong
            content:
              - d
          - >-
            ) Mutations were ranked according to their enrichment ratios,
            revealing that many (30%) of the top affinity-enhancing mutations
            occurred at the vL-vH interface (30 identities at the eight
            positions with enrichment over the parental identity above threefold
            are marked in blue triangles). (
          - type: Strong
            content:
              - e
          - >-
            ) Spheres indicate positions on the molecular structure of the bound
            HEL-D44.1 complex (PDB entry 1MLC) in which mutations exhibited at
            least threefold enrichment relative to D44.1. A cluster of enriched
            positions at the vL-vH interface, mostly belonging to the antibody
            framework, is highlighted in purple. HEL—hen egg-white lysozyme.
    label: Fig 1
    content:
      - type: ImageObject
        contentUrl: /tmp/df29ca476f578007aaa64ecd5608edb4/g001.png
        format: image/png
        meta:
          inline: false
          linkType: simple
  - type: Paragraph
    content:
      - >-
        We found affinity-enhancing mutations at 34 positions, mostly within the
        CDRs, as expected (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g001'
            content:
              - Fig 1C
      - >-
        ). We also noticed a surprisingly large cluster of eight positions at
        the vL-vH interface where affinity-enhancing mutations occurred,
        although they were not in direct contact with the antigen (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g001'
            content:
              - Fig 1D and 1E
      - >-
        ). This cluster of affinity-enhancing mutations in the vL-vH interface
        is intriguing for four reasons: (1) the vL-vH interface mediates the
        assembly of the Fv from the two antibody chains, and mutations in this
        region have the potential to also enhance stability through improved Fv
        assembly [
      - type: Cite
        target: pcbi-1007207-ref001
        content:
          - '1'
      - >-
        ]; (2) the genetic pairing of light and heavy chains during germline
        antibody generation is a random process which may result in suboptimal
        vL-vH interfaces, flexibility in the antigen-binding site [
      - type: Cite
        target: pcbi-1007207-ref034
        content:
          - '34'
      - '], and therefore in lower antigen affinity ['
      - type: Cite
        target: pcbi-1007207-ref035
        content:
          - '35'
      - >-
        ]; (3) this region is distant from the mutational hotspots in the CDRs
        and may not be fully optimized in the course of natural affinity
        maturation [
      - type: Cite
        target: pcbi-1007207-ref036
        content:
          - '36'
      - >-
        ]; and (4) antibody-engineering procedures, such as humanization or CDR
        grafting may inadvertently compromise the structural integrity of this
        region by mispairing CDRs and frameworks [
      - type: Cite
        target: pcbi-1007207-ref037
        content:
          - '37'
      - >-
        ]. Based on these considerations, we hypothesized that the vL-vH
        interface may be especially amenable to the design of multipoint mutants
        that simultaneously improve stability and affinity in both natural and
        engineered antibodies.
  - type: Paragraph
    content:
      - >-
        Combining mutations in densely packed protein cores, such as the vL-vH
        interface, is challenging, however, because inadvertently introduced
        voids, steric overlaps, or mispaired polar amino acid side-chains can
        lead to protein instability, misfolding, and aggregation [
      - type: Cite
        target: pcbi-1007207-ref021
        content:
          - '21'
      - ','
      - type: Cite
        target: pcbi-1007207-ref023
        content:
          - '23'
      - >-
        ]. We, therefore, asked whether the mutational-tolerance map could guide
        Rosetta design in finding improved multipoint mutants at the vL-vH
        interface. In preliminary calculations starting from the lysozyme-bound
        D44.1 structure (PDB entry: 1MLC), we restricted Rosetta combinatorial
        design to the eight positions and 38 identities (including the wild type
        identities) at these positions that showed at least threefold enrichment
        relative to D44.1 according to the mutational-tolerance map (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g001'
            content:
              - Fig 1B and 1E
      - >-
        ). The resulting design, however, comprised only three conservative
        mutations, suggesting that the dense packing and backbone rigidity at
        the vL-vH interface restricted sequence optimization. We, therefore,
        repeated design calculations but this time excluded the wild type
        identities at the eight positions, forcing the design of an optimal
        combination of mutations only from those that were substantially
        enriched in deep mutational scanning. We iterated sequence design and
        backbone and sidechain minimization to promote the acceptance of even
        radical mutations yielding design D44.1
      - type: Superscript
        content:
          - des
      - ' with eight mutations. As a preliminary qualitative test, we analyzed D44.1'
      - type: Superscript
        content:
          - des
      - ' binding to lysozyme and to seven of the eight single-point mutations formatted as scFvs using yeast display ['
      - type: Cite
        target: pcbi-1007207-ref003
        content:
          - '3'
      - >-
        ]. As expected, each of the point mutations improved the apparent
        binding affinity relative to D44.1; and yet, the multipoint D44.1
      - type: Superscript
        content:
          - des
      - ' exhibited a substantial improvement in apparent affinity compared to the single-point mutations ('
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s001'
            content:
              - S1B Fig
      - ).
  - type: Paragraph
    content:
      - >-
        To determine what molecular factors might underlie higher affinity in
        D44.1
      - type: Superscript
        content:
          - des
      - >-
        , we expressed the design as an antigen-binding fragment (Fab) and
        determined its structure by X-ray crystallography in the absence of
        lysozyme (
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s007'
            content:
              - S1 Table
      - '). Despite eight core mutations, the overall agreement between D44.1'
      - type: Superscript
        content:
          - des
      - ' and the bound structure of D44.1, which served as the starting point for designing D44.1'
      - type: Superscript
        content:
          - des
      - ', was excellent ('
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s002'
            content:
              - S2 Fig
      - >-
        ): The two structures deviated by <1 Å backbone root-mean-square
        deviation (rmsd) and in side-chain residues comprising the
        lysozyme-binding site. The mutations apparently improved various
        molecular aspects of the vL-vH interface including interface packing,
        solvation, and backbone rigidity (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g002'
            content:
              - Fig 2A
      - '). Next, we tested lysozyme binding by D44.1 and D44.1'
      - type: Superscript
        content:
          - des
      - ' (both expressed and purified as Fab) using surface-plasmon resonance (SPR). D44.1'
      - type: Superscript
        content:
          - des
      - ' exhibited nearly tenfold improvement in affinity ('
      - type: Emphasis
        content:
          - K
      - type: Subscript
        content:
          - type: Emphasis
            content:
              - D
      - ' of 15 versus 135 nM for D44.1'
      - type: Superscript
        content:
          - des
      - ' and D44.1, respectively), with a 25-fold slower off-rate (8 * 10'
      - type: Superscript
        content:
          - −4
      - ' s'
      - type: Superscript
        content:
          - '-1'
      - ) (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g002'
            content:
              - Fig 2B
      - ). D44.1
      - type: Superscript
        content:
          - des
      - ' also exhibited improved thermal denaturation and aggregation resistance ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g002'
            content:
              - Fig 2C and 2D
      - ).
  - type: Figure
    id: pcbi.1007207.g002
    caption:
      - type: Heading
        id: sec003
        depth: 2
        content:
          - >-
            Gains in affinity, stability, and aggregation resistance through
            vL-vH interface design guided by deep mutational scanning.
      - type: Paragraph
        content:
          - (
          - type: Strong
            content:
              - a
          - >-
            ) Comparison of the starting anti-lysozyme antibody D44.1 and the
            crystal structure of design D44.1
          - type: Superscript
            content:
              - des
          - ' (PDB entries: 1MLC and 6GC2, respectively) showed improved interactions across the interface and likely increased backbone rigidity. ('
          - type: Strong
            content:
              - b
          - >-
            ) SPR kinetic analysis of hen egg-white lysozyme (HEL) binding with
            threefold dilutions of HEL from a maximal concentration of 333 nM
            for D44.1 and 111 nM for D44.1
          - type: Superscript
            content:
              - des
          - ' (kinetic fits shown in gray). D44.1 exhibited '
          - type: Emphasis
            content:
              - k
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - a
          - ' = 1.5 * 10'
          - type: Superscript
            content:
              - '5'
          - ' M'
          - type: Superscript
            content:
              - '-1'
          - s
          - type: Superscript
            content:
              - '-1'
          - ', '
          - type: Emphasis
            content:
              - k
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - d
          - ' = 0.021 s'
          - type: Superscript
            content:
              - '-1'
          - ', and '
          - type: Emphasis
            content:
              - K
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - D
          - ' = 137 nM. D44.1'
          - type: Superscript
            content:
              - des
          - ' exhibited '
          - type: Emphasis
            content:
              - k
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - a
          - ' = 5.3 * 10'
          - type: Superscript
            content:
              - '4'
          - ' M'
          - type: Superscript
            content:
              - '-1'
          - s
          - type: Superscript
            content:
              - '-1'
          - ', '
          - type: Emphasis
            content:
              - k
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - d
          - ' = 7.9 * 10'
          - type: Superscript
            content:
              - −4
          - ' s'
          - type: Superscript
            content:
              - '-1'
          - ', and '
          - type: Emphasis
            content:
              - K
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - D
          - ' = 15 nM ('
          - type: Strong
            content:
              - c & d
          - >-
            ) Thermal denaturation and temperature of aggregation onset,
            respectively, of D44.1 and D44.1
          - type: Superscript
            content:
              - des
          - ' formatted as Fabs using microscale thermophoresis. ('
          - type: Strong
            content:
              - e
          - >-
            ) A potential molecular explanation for improved affinity. The
            unbound (cyan) and bound (gray) structures of D44.1 (PDB entries:
            1MLB and 1MLC, respectively) exhibit a different H2 backbone
            conformation; the former sterically hinders lysozyme binding. The
            high-affinity anti-lysozyme antibody F10.6.6 in its unbound form
            (PDB entry: 2Q76; orange) and D44.1
          - type: Superscript
            content:
              - des
          - ' (pink) are similar to one another and to the bound conformation of D44.1 and are compatible with binding HEL. (inset) a closeup of the H2 backbone conformation revealing that the D44.1 H2 backbone (cyan) sterically overlaps with lysozyme, whereas all the other backbone conformations are compatible with lysozyme binding. The Trp47'
          - type: Superscript
            content:
              - H
          - Tyr mutation in D44.1
          - type: Superscript
            content:
              - des
          - ' alters packing at the base of CDR H2 and may induce the observed conformational change in the design.'
    label: Fig 2
    content:
      - type: ImageObject
        contentUrl: /tmp/df29ca476f578007aaa64ecd5608edb4/g002.png
        format: image/png
        meta:
          inline: false
          linkType: simple
  - type: Paragraph
    content:
      - We also compared the molecular structure of D44.1
      - type: Superscript
        content:
          - des
      - ' to the unbound structure of D44.1 (PDB entry: 1MLB). The main difference between the two structures was localized to the backbone conformation of CDR H2: Whereas H2 in the unbound structure of D44.1 adopts a conformation that would sterically overlap with lysozyme in the bound structure, the H2 backbone of D44.1'
      - type: Superscript
        content:
          - des
      - ' moves away from this position such that, even in the unbound state, the design is sterically compatible with lysozyme binding. The H2 backbone conformation of D44.1'
      - type: Superscript
        content:
          - des
      - ' is not identical but is similar to the H2 conformation in the bound D44.1 structure and also to the conformation observed in the unbound structure of the high-affinity anti-lysozyme antibody F10.6.6 (PDB entry: 1P2C) ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g002'
            content:
              - Fig 2E
      - >-
        ). Although it is possible that the observed conformational differences
        among the structures are due to differences in crystallographic
        conditions, we note that the mutation Trp47
      - type: Superscript
        content:
          - H
      - Tyr in D44.1
      - type: Superscript
        content:
          - des
      - ' is incompatible with the observed H2 conformation in the unbound state of D44.1 and may induce the observed change in the design’s backbone conformation. Hence, the structure-based analysis suggested that the design of the vL-vH interface based on the bound antibody structure might increase the compatibility of the CDR backbones for the ligand while simultaneously improving stability.'
  - type: Heading
    id: sec004
    depth: 2
    content:
      - Computational mutation-tolerance mapping
  - type: Paragraph
    content:
      - >-
        The successful optimization of antibody affinity and stability
        encouraged us to fully automate the design procedure, eliminating the
        requirement for experimental deep mutational scanning. We, therefore,
        sought a general computational strategy that would predict which
        mutations in the vL-vH interface were likely to enhance affinity and
        stability, with the goal of developing a general computational procedure
        for mutational-tolerance mapping. To achieve this goal, we exploited the
        large experimental dataset of the D44.1 mutational tolerance map,
        comprising 2,294 point mutations, for training. At each of the mutated
        D44.1 Fv positions, we used Rosetta to compute the changes to
        native-state energy due to each of the 19 amino acid mutations (ΔΔ
      - type: Emphasis
        content:
          - G
      - >-
        ). Using a multiple-sequence alignment of homologous Fvs, we
        additionally computed each point mutation’s evolutionary-conservation
        score, as represented in a Position-Specific Scoring Matrix (PSSM) [
      - type: Cite
        target: pcbi-1007207-ref038
        content:
          - '38'
      - >-
        ]. These two computed parameters provide complementary predictions of
        mutational tolerance: the former predicts the impact of a mutation on
        native-state stability and the latter discriminates between
        evolutionarily tolerated mutations and those that have been purged by
        evolution. The use of these two parameters has recently led to
        substantial improvement in design accuracy in binder and enzyme design
        challenges in our laboratory [
      - type: Cite
        target: pcbi-1007207-ref020
        content:
          - '20'
      - –
      - type: Cite
        target: pcbi-1007207-ref022
        content:
          - '22'
      - ','
      - type: Cite
        target: pcbi-1007207-ref038
        content:
          - '38'
      - –
      - type: Cite
        target: pcbi-1007207-ref043
        content:
          - '43'
      - >-
        ]. We specifically used these two parameters because they can be
        computed for any antibody given an accurate experimental or model
        structure, allowing us, in principle, to compute mutational tolerance
        maps for any antibody Fv.
  - type: Paragraph
    content:
      - We systematically screened different combinations of ΔΔ
      - type: Emphasis
        content:
          - G
      - ' and PSSM thresholds to determine which combination optimally discriminates enhancing from deleterious mutations as observed in the experimental mutational-tolerance map of D44.1. We defined the prediction true-positive rate (TPR) as the proportion of correctly predicted affinity-enhancing mutations (>1.5-fold enrichment according to deep mutational scanning) and the true-negative rate (TNR) as the proportion of correctly predicted deleterious ones (enrichment ratio <1). The resulting phase space of (PSSM, ΔΔ'
      - type: Emphasis
        content:
          - G
      - >-
        ) thresholds revealed an expected tradeoff, wherein high TNR came at the
        cost of low TPR, and 
      - type: Emphasis
        content:
          - vice versa
      - ' ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g003'
            content:
              - Fig 3A
      - >-
        ). The likelihood of obtaining a multipoint mutant without a single
        deleterious mutation can be roughly approximated by TNR
      - type: Superscript
        content:
          - type: Emphasis
            content:
              - 'n'
      - ', where '
      - type: Emphasis
        content:
          - 'n'
      - ' is the number of mutations. Given the large size of the vL-vH interface (20–30 positions ['
      - type: Cite
        target: pcbi-1007207-ref044
        content:
          - '44'
      - >-
        ]), we aimed for a large maximum number of mutations in each multipoint
        mutant (
      - type: Emphasis
        content:
          - 'n'
      - ' = 10) and therefore selected a stringent cutoff TNR = 94%, providing a rough estimate that 50% of designs with ten mutations would not contain a single deleterious mutation ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g003'
            content:
              - Fig 3B
      - >-
        ). At this high TNR, the TPR is only 40%, reflecting the challenging
        tradeoff in the design of multipoint variants. We anticipate that in
        certain applications, such as in the design of improved antibodies for
        therapeutic application, a smaller number of mutations may be preferred.
        In such cases, a lower TNR and therefore a higher TPR may be
        implemented, and 
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g003'
            content:
              - Fig 3C
      - ' provides a guide for choosing different (PSSM, ΔΔ'
      - type: Emphasis
        content:
          - G
      - >-
        ) thresholds. Instructions for computing a mutation-tolerance map based
        on any structure of an antibody Fv are available as Supplemental Data,
        and the AbLIFT web server enables user control of these parameters.
  - type: Figure
    id: pcbi.1007207.g003
    caption:
      - type: Heading
        id: sec004
        depth: 2
        content:
          - >-
            Mutational-tolerance mapping by Rosetta atomistic energy
            calculations (ΔΔ
          - type: Emphasis
            content:
              - G
          - ) and evolutionary-conservation scores (PSSM).
      - type: Paragraph
        content:
          - (
          - type: Strong
            content:
              - a
          - ) Systematic analysis of combinations of PSSM and ΔΔ
          - type: Emphasis
            content:
              - G
          - ' thresholds reveals an expected tradeoff in prediction accuracy of mutational tolerance. Each combination of thresholds (-10≤PSSM≤10; -10≤ΔΔ'
          - type: Emphasis
            content:
              - G
          - >-
            ≤20 Rosetta energy units, R.e.u.) results in a different fraction of
            correctly predicted enhancing or deleterious mutations
            (true-positive rate [TPR] and true-negative rate [TNR],
            respectively) observed in the deep mutational scanning data of
            D44.1. (
          - type: Strong
            content:
              - b
          - ') All (PSSM, ΔΔ'
          - type: Emphasis
            content:
              - G
          - >-
            ) combinations are plotted with their TPR and TNR values, and the
            Pareto-optimal front is indicated in orange. Several combinations of
            (PSSM, ΔΔ
          - type: Emphasis
            content:
              - G
          - ) thresholds are indicated by blue triangles. (
          - type: Strong
            content:
              - c
          - ') The thresholds (PSSM≥-1, ΔΔ'
          - type: Emphasis
            content:
              - G
          - >-
            ≤+1 R.e.u.) result in a TNR of 94% and TPR of 40% and were used in
            subsequent design calculations. Optimal ΔΔ
          - type: Emphasis
            content:
              - G
          - ' cutoffs may vary depending on the energy function and the relaxation protocol. For details on these choices, see '
          - type: Link
            relation: sec
            target: '#sec007'
            content:
              - Methods
          - .
    label: Fig 3
    content:
      - type: ImageObject
        contentUrl: /tmp/df29ca476f578007aaa64ecd5608edb4/g003.png
        format: image/png
        meta:
          inline: false
          linkType: simple
  - type: Heading
    id: sec005
    depth: 2
    content:
      - Automated affinity and stability design in the vL-vH interface
  - type: Paragraph
    content:
      - >-
        We next sought to develop a general and fully automated design protocol
        for improving molecular interactions across the vL-vH interface. AbLIFT
        starts by computing a mutational-tolerance map at the vL-vH interface
        using the approach described above; it then exhaustively enumerates the
        multipoint combinations of tolerated mutations; ranks them by energy,
        and selects low-energy variants for experimental testing. This algorithm
        resembles our recently described FuncLib method for designing
        functionally diverse enzyme repertoires [
      - type: Cite
        target: pcbi-1007207-ref041
        content:
          - '41'
      - >-
        ], with the key differences that AbLIFT is applied to the core of
        obligatory binding surfaces rather than to solvent-exposed surfaces and
        most importantly, AbLIFT does not require an initial design round of
        protein stabilization.
  - type: Paragraph
    content:
      - >-
        To validate AbLIFT, we chose two antibodies as subjects for design: the
        synthetic antibody G6, which targets human Vascular-Endothelial Growth
        Factor (VEGF) [
      - type: Cite
        target: pcbi-1007207-ref045
        content:
          - '45'
      - >-
        ], and an engineered variant of the 492.1 antibody, designated h492.1,
        which targets human Quiescin Sulfhydryl Oxidase 1 (QSOX1). QSOX1 is a
        multi-domain disulfide-catalyst that is overproduced in tumors [
      - type: Cite
        target: pcbi-1007207-ref046
        content:
          - '46'
      - '] and is a potential drug target ['
      - type: Cite
        target: pcbi-1007207-ref047
        content:
          - '47'
      - ','
      - type: Cite
        target: pcbi-1007207-ref048
        content:
          - '48'
      - >-
        ]. These antibodies are unrelated to D44.1 or to one another and are the
        products of protein engineering. G6 is widely used in animal studies and
        resulted from a phage-displayed synthetic Fab library of the light chain
        with a heavy chain sequence of an anti-mVEGF antibody (
      - type: Emphasis
        content:
          - K
      - type: Subscript
        content:
          - type: Emphasis
            content:
              - D
      - ' approximately 1 nM) ['
      - type: Cite
        target: pcbi-1007207-ref049
        content:
          - '49'
      - >-
        ]. The h492.1 antibody was obtained by fusing the variable domains from
        the high-affinity (
      - type: Emphasis
        content:
          - K
      - type: Subscript
        content:
          - type: Emphasis
            content:
              - D
      - ' approximately 1 nM) QSOX1-inhibiting murine antibody 492.1 onto a human IgG scaffold. Following this fusion, h492.1 could not be expressed to detectable levels in a recombinant cultured human cell system, frustrating its further development. Thus, with these two targets, we sought to test the ability of AbLIFT to optimize high-affinity antibodies that resulted from conventional antibody-engineering procedures, whether well-behaved ones (G6) or ones that showed low (or no) detectable expression levels (h492.1).'
  - type: Paragraph
    content:
      - >-
        The computed mutational-tolerance map of G6 (starting from its bound
        structure, PDB entry 2FJG) at 30 vL-vH interface positions defined 26
        affinity-enhancing mutations at 11 positions. To achieve significant
        improvement of vL-vH interface packing, we sought to design multipoint
        mutants with 4–10 mutations relative to G6, resulting in a tolerated
        sequence space of 203,835 unique multipoint mutants. All multipoint
        mutants were modeled in Rosetta, including by a backbone and side-chain
        minimization step, which is essential for enabling cavity-filling
        small-to-large mutations [
      - type: Cite
        target: pcbi-1007207-ref050
        content:
          - '50'
      - ','
      - type: Cite
        target: pcbi-1007207-ref051
        content:
          - '51'
      - >-
        ], and the models were then ranked by energy. 53% of the mutants
        (>100,000) exhibited energies as favorable as or better than the
        G6-bound antibody. Therefore, although the exhaustive enumeration of
        this large number of mutants is computationally demanding (approximately
        6,000-CPU hours), the very large number of potentially improved designs
        makes a compelling case for exhaustive enumeration and ranking of
        variants within the tolerated sequence space. Furthermore, the computed
        mutational-tolerance map focuses exhaustive enumeration on a subset of
        stable multipoint mutants within the vast hypothetical sequence space of
        mutants at the vL-vH interface (20
      - type: Superscript
        content:
          - '30'
      - ' = 10'
      - type: Superscript
        content:
          - '39'
      - ' unique sequences), >99% of which are predicted to have reduced stability compared to the parental antibody ('
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s003'
            content:
              - S3 Fig
      - ).
  - type: Paragraph
    content:
      - >-
        We clustered the designs, eliminating ones that had fewer than four
        mutations relative to one another and selected the 18 lowest-energy ones
        for experimental testing. The designs were formatted as scFvs, and their
        binding signals relative to the G6 antibody were first qualitatively
        measured at 8 nM VEGF concentration using yeast display [
      - type: Cite
        target: pcbi-1007207-ref003
        content:
          - '3'
      - '] ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g004'
            content:
              - Fig 4A
      - >-
        ). Encouragingly, seven designs (approximately 40%) showed comparable or
        higher binding signal at this concentration. The best two designs, G6
      - type: Superscript
        content:
          - des1
      - ' and G6'
      - type: Superscript
        content:
          - des13
      - >-
        , were expressed as Fabs. When subjected to Ni-NTA purification, G6
        exhibited multiple bands, indicative of sample heterogeneity, whereas,
        remarkably, both designs eluted mostly in the size expected for a Fab (
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s004'
            content:
              - S4A and S4B Fig
      - ') ['
      - type: Cite
        target: pcbi-1007207-ref052
        content:
          - '52'
      - '].'
  - type: Figure
    id: pcbi.1007207.g004
    caption:
      - type: Heading
        id: sec005
        depth: 2
        content:
          - >-
            Fully automated antibody stability and affinity optimization using
            AbLIFT.
      - type: Paragraph
        content:
          - (
          - type: Strong
            content:
              - a
          - >-
            ) G6 and 18 low-energy designs, each encoding 4–10 mutations
            relative to G6 (number of mutations is indicated above the bars)
            were tested for binding using yeast display at 8 nM VEGF
            concentration, resulting in seven designs that showed comparable or
            higher binding signal compared to G6. G6
          - type: Superscript
            content:
              - des1
          - ' and G6'
          - type: Superscript
            content:
              - des13
          - ' were chosen for further characterization (colored in blue and orange, respectively). ('
          - type: Strong
            content:
              - b
          - >-
            ) SPR kinetic analysis of VEGF binding with twofold dilutions from a
            maximal concentration of 100 nM by G6, G6
          - type: Superscript
            content:
              - des1
          - ', and G6'
          - type: Superscript
            content:
              - des13
          - ' Fabs demonstrated faster binding on-rate in the designs ('
          - type: Emphasis
            content:
              - k
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - a
          - ' = 2.3 * 10'
          - type: Superscript
            content:
              - '5'
          - ' M'
          - type: Superscript
            content:
              - '-1'
          - s
          - type: Superscript
            content:
              - '-1'
          - ', 3.27 * 10'
          - type: Superscript
            content:
              - '5'
          - ' M'
          - type: Superscript
            content:
              - '-1'
          - s
          - type: Superscript
            content:
              - '-1'
          - ' and 5.3 * 10'
          - type: Superscript
            content:
              - '5'
          - ' M'
          - type: Superscript
            content:
              - '-1'
          - s
          - type: Superscript
            content:
              - '-1'
          - ', respectively). G6'
          - type: Superscript
            content:
              - des13
          - ' also improved binding off-rate ('
          - type: Emphasis
            content:
              - k
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - d
          - ' = 3.2 * 10'
          - type: Superscript
            content:
              - −5
          - ' s'
          - type: Superscript
            content:
              - '-1'
          - ' compared to 6 * 10'
          - type: Superscript
            content:
              - −5
          - ' s'
          - type: Superscript
            content:
              - '-1'
          - ' in G6), resulting in an improved dissociation constant ('
          - type: Emphasis
            content:
              - K
          - type: Subscript
            content:
              - type: Emphasis
                content:
                  - D
          - ' = 60 pM compared to 270 pM in G6). ('
          - type: Strong
            content:
              - c & d
          - >-
            ) Thermal denaturation and temperature of aggregation onset
            experiments, respectively, using microscale thermophoresis indicated
            substantially higher apparent stability in the designs. (
          - type: Strong
            content:
              - e
          - >-
            ) Computational mutation-tolerance mapping indicated 11 positions at
            the vL-vH interface of the anti-VEGF antibody G6 (spheres) with
            potentially tolerated mutations. Thumbnails indicate selected
            mutations in a model structure of G6
          - type: Superscript
            content:
              - des13
          - ' relative to G6 (gray). ('
          - type: Strong
            content:
              - f
          - >-
            ) Expression levels in HEK293 cells of G6 and the designs formatted
            as IgG were measured using Western blot analysis showing
            approximately an order of magnitude improvement in IgG expression
            levels for the designs. 
          - type: Strong
            content:
              - (g)
          - ' Native mass-spectrometry analysis exhibited higher tolerance to applied collision energy in G6'
          - type: Superscript
            content:
              - des13
          - ' compared to G6, both formatted as IgG. The error bars represent standard deviations inferred from three repeats.'
    label: Fig 4
    content:
      - type: ImageObject
        contentUrl: /tmp/df29ca476f578007aaa64ecd5608edb4/g004.png
        format: image/png
        meta:
          inline: false
          linkType: simple
  - type: Paragraph
    content:
      - 'Next, the designs’ affinities for VEGF were determined using SPR ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g004'
            content:
              - Fig 4B
      - '). Both designs improved binding on-rate, and G6'
      - type: Superscript
        content:
          - des13
      - ' also improved the off-rate, resulting in fivefold improvement in '
      - type: Emphasis
        content:
          - K
      - type: Subscript
        content:
          - type: Emphasis
            content:
              - D
      - ' relative to G6. Both designs also exhibited substantial improvements in thermal stability and the temperature of aggregation onset (19° C and 10° C, respectively) ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g004'
            content:
              - Fig 4C and 4D
      - ). We examined the model structure of G6
      - type: Superscript
        content:
          - des13
      - >-
        , which comprised six mutations at the vL-vH interface relative to G6,
        finding that the mutations were likely to improve the interface through
        backbone rigidification and the introduction of a new buried polar
        hydrogen-bond network (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g004'
            content:
              - Fig 4E
      - >-
        ). Such cooperative interaction networks do not typically arise in
        conventional antibody affinity-maturation processes (either in nature or
        the laboratory), which select mutations in a stepwise manner and are
        therefore biased towards additive rather than cooperative multipoint
        mutations. Introducing accurate new polar interaction networks is also a
        fundamental challenge for computational design [
      - type: Cite
        target: pcbi-1007207-ref053
        content:
          - '53'
      - ','
      - type: Cite
        target: pcbi-1007207-ref054
        content:
          - '54'
      - >-
        ] and the use of evolutionary constraints during design has recently
        been shown to overcome this challenge [
      - type: Cite
        target: pcbi-1007207-ref042
        content:
          - '42'
      - '].'
  - type: Paragraph
    content:
      - >-
        We next tested the stability and expressibility of the VEGF designs
        formatted as full-length IgGs. We expressed G6, G6
      - type: Superscript
        content:
          - des1
      - ', and G6'
      - type: Superscript
        content:
          - des13
      - ' in HEK293 cells and found that the designs exhibited nearly an order of magnitude higher expression level than G6 ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g004'
            content:
              - Fig 4F
      - ). We next measured the relative stabilities of G6 and G6
      - type: Superscript
        content:
          - des13
      - ' using native mass spectrometry ['
      - type: Cite
        target: pcbi-1007207-ref055
        content:
          - '55'
      - '] under reducing conditions by titrating the collision energy ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g004'
            content:
              - Fig 4G
      - >-
        ). We found that G6 IgG disassembly started at lower collision energy
        compared to G6
      - type: Superscript
        content:
          - des13
      - ', indicative of the design’s higher stability ('
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s005'
            content:
              - S5 Fig
      - >-
        ). We, therefore, concluded that AbLIFT could substantially improve
        expressibility, stability, and affinity, regardless of whether the
        antibody was formatted as Fab or IgG.
  - type: Paragraph
    content:
      - >-
        We applied the same computational strategy to h492.1, in which the Fv
        was derived from a murine antibody and the constant regions were derived
        from human IgG1. Since h492.1 failed to show detectable expression in
        HEK293 cell cultures, we started the computational design from the
        structure of the murine 492.1 parental antibody in complex with QSOX1
        (PDB entry: 4IJ3) [
      - type: Cite
        target: pcbi-1007207-ref047
        content:
          - '47'
      - >-
        ]. We selected the 20 lowest-energy, sequence-clustered AbLIFT designs,
        fused them to human IgG1 constant domains and subjected them to
        HEK293-expression screening from crude cell lysate supernatant. Dot-blot
        analysis showed detectable expression levels for all 20 designs, in
        clear contrast with the lack of detectable expression for h492.1 (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g005'
            content:
              - Fig 5A
      - >-
        ). We further quantitated expression levels using Western blot,
        revealing substantial variation in the expression levels among the
        designs (
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g005'
            content:
              - Fig 5B
      - >-
        ). In parallel, we examined the levels of QSOX1 inhibition by the 20
        designs, finding that 50% showed high levels of QSOX1 inhibition (
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s006'
            content:
              - S6 Fig
      - '). Based on activities and expression levels, we selected h492.1'
      - type: Superscript
        content:
          - des3
      - ' and h492.1'
      - type: Superscript
        content:
          - des18
      - ' for further analysis. These designs were purified and added to QSOX1 activity assays to test for inhibition. h492.1'
      - type: Superscript
        content:
          - des18
      - ' showed comparable inhibitory levels to the murine parent antibody when provided at equimolar amounts to a typical physiological concentration of QSOX1 (25 nM) as found in human serum ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g005'
            content:
              - Fig 5C
      - ') ['
      - type: Cite
        target: pcbi-1007207-ref056
        content:
          - '56'
      - ']. This analysis demonstrated that h492.1'
      - type: Superscript
        content:
          - des18
      - ' almost completely recovered the activity of the parental antibody while gaining high expression levels (approximately 75 mg/L supernatant). Structural analysis indicated that this design improved packing at the vL-vH interface ('
      - type: Strong
        content:
          - type: Link
            relation: fig
            target: '#pcbi-1007207-g005'
            content:
              - Fig 5D
      - >-
        ), demonstrating that in some cases optimizing this region could have a
        dramatic effect on the expression levels of engineered antibodies.
  - type: Figure
    id: pcbi.1007207.g005
    caption:
      - type: Heading
        id: sec005
        depth: 2
        content:
          - >-
            Substantial increase in antibody expression yields following AbLIFT
            design.
      - type: Paragraph
        content:
          - (
          - type: Strong
            content:
              - a
          - >-
            ) Dot blot analysis showed no detectable expression for h492.1 in
            HEK293 cells, whereas all 20 designs showed detectable levels of
            expression. (
          - type: Strong
            content:
              - b
          - >-
            ) Relative expression levels of the 20 designs using Western blot
            analysis. h492.1
          - type: Superscript
            content:
              - des3
          - ' and h492.1'
          - type: Superscript
            content:
              - des18
          - ' showed high expression and were selected for further analysis. ('
          - type: Strong
            content:
              - c
          - >-
            ) QSOX1 inhibitory activity assay using the parental 492.1 antibody
            and two designs. The inhibitory activity was measured for each
            antibody in a sulfhydryl oxidase assay using a physiological
            concentration of QSOX1 (25 nM). h492.1
          - type: Superscript
            content:
              - des18
          - ' showed comparable inhibitory activity relative to the parental antibody, with only a slight decrease when provided at sub-stoichiometric amounts (10 nM). ('
          - type: Strong
            content:
              - d
          - ) The structural context of mutations in h492.1
          - type: Superscript
            content:
              - des18
          - ' (color) relative to the experimental structure of 492.1 (gray). Spheres indicate the locations of the mutations, and the thumbnail shows two of the four designed mutations, which improve interchain packing and rigidify the backbone at the vL-vH interface according to the model structure.'
    label: Fig 5
    content:
      - type: ImageObject
        contentUrl: /tmp/df29ca476f578007aaa64ecd5608edb4/g005.png
        format: image/png
        meta:
          inline: false
          linkType: simple
  - type: Paragraph
    content:
      - >-
        Finally, we asked whether there were any sequence features in common
        among the designs (
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s009'
            content:
              - S3
          - ' and '
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s010'
            content:
              - S4
          - ' Tables'
      - '). Strikingly, position 43'
      - type: Superscript
        content:
          - L
      - ' (Chothia numbering) was mutated to Pro in D44.1'
      - type: Superscript
        content:
          - des
      - ' and in >60% of the G6 and h492.1 designs. Position 43'
      - type: Superscript
        content:
          - L
      - ' is located in a tight turn that connects two neighboring β strands, away from the CDRs, but Pro is not the consensus identity at this position (Ala and Ser are preferred). Furthermore, mutations at this position may have an important effect on the rigid-body angle formed by the variable light and heavy domains ['
      - type: Cite
        target: pcbi-1007207-ref044
        content:
          - '44'
      - ','
      - type: Cite
        target: pcbi-1007207-ref057
        content:
          - '57'
      - >-
        ], and it is, therefore, unlikely that this mutation would universally
        improve antibody stability and affinity. Other than this mutation to
        Pro, we did not observe common sequence features among the designs.
        Overlapping but non-identical sets of positions were varied in each of
        the three case studies presented here, and the mutations at aligned
        positions were dissimilar. We, therefore, concluded that the designs
        improved interactions across the vL-vH interface through a variety of
        mechanisms that depended on the specific molecular structure of the
        parental antibodies.
  - type: Heading
    id: sec006
    depth: 1
    content:
      - Discussion
  - type: Paragraph
    content:
      - >-
        Our study demonstrates that improved interactions across the vL-vH
        interface may result in substantial optimization of a range of essential
        parameters for antibody development, including expressibility,
        stability, and affinity. The automated AbLIFT strategy enables the
        design of cooperative networks of multipoint mutations in the antibody
        core that are likely to be inaccessible to experimental affinity
        maturation processes since these latter methods select mutations in a
        stepwise manner. Since AbLIFT impacts the antibody core and does not
        alter the structure of the antigen-binding site, the designed mutations
        cooperate with surface mutations identified through conventional
        antibody-engineering processes to further increase affinity and
        stability. AbLIFT may be particularly beneficial in antibodies, such as
        G6 and h492.1, which were the product of antibody-engineering approaches
        that might compromise antibody structural integrity, resulting in
        reduced affinity or stability. Moreover, antibody structure-prediction
        methods now often produce atomically accurate models at the vL-vH
        interface (though still not at the CDR H3) [
      - type: Cite
        target: pcbi-1007207-ref058
        content:
          - '58'
      - –
      - type: Cite
        target: pcbi-1007207-ref060
        content:
          - '60'
      - >-
        ], suggesting that by restricting design to the framework regions,
        AbLIFT may in some cases enable antibody optimisation even in the
        absence of an experimental structure. We note, however, that AbLIFT
        considers only phylogenetic information and molecular energetics and
        disregards immunogenicity, which may be an important consideration in
        antibodies developed for clinical use. To address this concern, the
        AbLIFT web server enables complete control over the design sequence
        space and can be used to eliminate mutations with immunogenic potential.
  - type: Paragraph
    content:
      - >-
        The surprisingly broad ability of vL-vH design to optimize antibody
        properties is consistent with the Colman interface-adaptor hypothesis,
        according to which the formation of the Fv from two chains renders it
        flexible [
      - type: Cite
        target: pcbi-1007207-ref034
        content:
          - '34'
      - >-
        ]. According to this hypothesis, Fv flexibility is likely to be an
        adaptive property selected by evolution to broaden molecular recognition
        by each individual antibody to a range of antigens through induced fit
        or conformational selection [
      - type: Cite
        target: pcbi-1007207-ref061
        content:
          - '61'
      - >-
        ], thereby solving the conundrum of how a large but finite antibody
        repertoire could recognize a potentially infinite range of antigens [
      - type: Cite
        target: pcbi-1007207-ref062
        content:
          - '62'
      - >-
        ]. Flexibility, however, might come at a cost, since an Fv that exhibits
        flexible vL-vH pairing may occupy multiple molecular states that compete
        with the binding-competent state, thus lowering antigen-binding
        affinity. Flexibility may moreover result in misfolding or transient
        dissociation of the two variable chains, resulting in terminal
        aggregation or degradation by the cellular proteostasis machinery,
        thereby lowering expression yields. In extreme cases, poorly defined
        packing at the vL-vH interface can lead to substantial rearrangements of
        the antibody variable domain during binding [
      - type: Cite
        target: pcbi-1007207-ref063
        content:
          - '63'
      - >-
        ], and such rearrangements could lower antigen-binding affinity and
        specificity. Therefore, while the interface-adaptor hypothesis neatly
        explains why flexibility at the vL-vH interface is advantageous in early
        steps of antibody selection, broad specificity and marginal vL-vH
        interface stability become liabilities in later stages of antibody
        development into research or therapeutic tools. We anticipate that
        AbLIFT will have a wide scope to automatically and reliably improve
        stability, solubility, expressibility, affinity, and structural
        integrity in numerous antibodies in which these important properties are
        compromised.
  - type: Heading
    id: sec007
    depth: 1
    content:
      - Methods
  - type: Heading
    id: sec008
    depth: 2
    content:
      - D44.1 genetic library construction
  - type: Paragraph
    content:
      - >-
        Forward and reverse primers with the degenerate codon NNS were generated
        for all 135 positions on the Fv of D44.1, essentially as described [
      - type: Cite
        target: pcbi-1007207-ref064
        content:
          - '64'
      - >-
        ]. Primers were ordered from Sigma (Sigma-Aldrich, Rehovot, Israel) and
        were used to introduce all possible amino acids per position by
        QuickChange mutagenesis [
      - type: Cite
        target: pcbi-1007207-ref065
        content:
          - '65'
      - >-
        ]. Next, the PCR product of each position was transformed into yeast
        (EBY100 cells) and plated on SD-Trp as described [
      - type: Cite
        target: pcbi-1007207-ref066
        content:
          - '66'
      - >-
        ]. Briefly, plates with more than 400 colonies were scraped with 1 ml
        SDCAA, 50 μl was added to 5 ml SDCAA tube and cells were then grown at
        30°C overnight. The point mutants were split into six libraries,
        corresponding to positions that were at most 130 bp apart from one
        another to enable deep mutational scanning using 150 bp reads.
  - type: Heading
    id: sec009
    depth: 2
    content:
      - Yeast surface display selection for libraries
  - type: Paragraph
    content:
      - 'Yeast-display experiments were conducted essentially as described ['
      - type: Cite
        target: pcbi-1007207-ref003
        content:
          - '3'
      - >-
        ]. Briefly, yeast cells were grown in selective medium SDCAA overnight
        at 30°C. The cells were then resuspended in 10 ml induction medium and
        incubated at 20°C for 20 h. 10
      - type: Superscript
        content:
          - '7'
      - ' cells were then used for yeast-cell surface display experiments: cells were subjected to primary antibody (mouse monoclonal IgG1 anti-c-Myc (9E10) sc-40, Santa Cruz Biotechnology) for expression monitoring and biotinylated ligand at 90 nM lysozyme (GeneTex) in PBS-F for 30 min at room temperature. The cells then underwent a second staining with fluorescently labeled secondary antibody (AlexaFluor488—goat-anti-mouse IgG1 (Life Technologies) for scFv labeling, Streptavidin-APC (SouthernBiotech) for ligand labeling) for 10 min at 4°C. Next, the cell fluorescence was measured and cells were collected under sorting conditions for expression and top 15% binders. The selection gates were calibrated using the wild-type scFv D44.1 and these gates were subsequently applied to the library constructs. Following fluorescence-activated cell sorting (FACS), cells were grown in SDCAA for 1–2 days and plasmids were extracted using Zymoprep Yeast Plasmid Miniprep II kit (Zymo Research).'
  - type: Heading
    id: sec010
    depth: 2
    content:
      - Yeast surface display of anti-VEGF scFvs
  - type: Paragraph
    content:
      - >-
        18 designs of improved binding affinity antibodies against VEGF and the
        wild-type G6 Fvs were ordered from Twist Biosciences as scFvs. These, as
        described above, were amplified by PCR and cloned into pCTCon2 using
        homologous recombination in yeast [
      - type: Cite
        target: pcbi-1007207-ref066
        content:
          - '66'
      - >-
        ]. The plasmids were extracted by Zymoprep kit II, transformed into
        bacteria for sequence validation and verified clones were transformed to
        yeast for display [
      - type: Cite
        target: pcbi-1007207-ref003
        content:
          - '3'
      - >-
        ]. The wild-type and designed antibodies were tested for binding by flow
        cytometry with 8 nM biotinylated VEGF (Recombinant Human VEGF 165,
        Biotinylated Protein R&D systems).
  - type: Heading
    id: sec011
    depth: 2
    content:
      - DNA preparation for deep sequencing
  - type: Paragraph
    content:
      - >-
        To connect the DNA adaptors for deep sequencing, the plasmids extracted
        from the libraries were amplified using Phusion High-Fidelity DNA
        Polymerase (ThermoFisher) in a two-step PCR protocol.
  - type: Paragraph
    content:
      - 'PCR 1:'
  - type: Paragraph
    content:
      - '(barcode: CTCTTTCCCTACACGACGCTCTTCCGATCT)'
  - type: Paragraph
    content:
      - '>forward (seg1):'
      - type: Strong
        content:
          - <barcode>
      - AGGGTCGGCTAGCCATATG
  - type: Paragraph
    content:
      - '>forward (seg2):'
      - type: Strong
        content:
          - <barcode>
      - GGATCGAATGGGTTAAACAACGT
  - type: Paragraph
    content:
      - '>forward (seg3):'
      - type: Strong
        content:
          - <barcode>
      - ACACCTCCTCTAACACCGC
  - type: Paragraph
    content:
      - '>forward (seg4):'
      - type: Strong
        content:
          - <barcode>
      - CTGGTGGCGGTGGCTC
  - type: Paragraph
    content:
      - '>forward (seg5):'
      - type: Strong
        content:
          - <barcode>
      - GCCGTGCGTCTCAGTCTATT
  - type: Paragraph
    content:
      - '>forward (seg6): '
      - type: Strong
        content:
          - <barcode>
      - CCATCTCGTTTCTCCGGC
  - type: Paragraph
    content:
      - '>reverse: '
      - type: Strong
        content:
          - CTGGAGTTCAGACGTGTGCTCTTCCGATCT
      - GGATCGAATGGGTTAAACAACGT
  - type: Paragraph
    content:
      - >-
        The PCR product for each population (expressed and top 15% of binders
        for each of the six libraries) was cleaned using Agencourt AMPure XP
        (Beckman Coulter, Inc.) and 1 μl from a 1:10 dilution was taken to the
        next PCR step for index labeling using KAPA Hifi DNA-polymerase (Kapa
        Biosystems, London, England):
  - type: Paragraph
    content:
      - '>forward: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGC'
  - type: Paragraph
    content:
      - '>reverse: CAAGCAGAAGACGGCATACGAGAT<index>GTGACTGGAGTTCAGACGTGTGC'
  - type: Paragraph
    content:
      - 'Top 15%—index: CAATAGTC'
  - type: Paragraph
    content:
      - 'Expressed—index: TTGAGCCT'
  - type: Paragraph
    content:
      - >-
        All the primers were ordered as PAGE-purified oligos. The concentration
        of the PCR product was measured using Qu-bit assay (Life Technologies,
        Grand Island, New York).
  - type: Heading
    id: sec012
    depth: 2
    content:
      - Deep-sequencing runs
  - type: Paragraph
    content:
      - >-
        DNA samples were run on an Illumina MiSeq using 150-bp paired-end kits.
        The FASTQ sequence files were obtained for each run, and customized
        scripts were used to generate the selection heat maps from the data as
        previously described [
      - type: Cite
        target: pcbi-1007207-ref064
        content:
          - '64'
      - >-
        ]. Briefly, the script starts by translating the DNA sequence to amino
        acid sequence; eliminates sequences that harbor more than one amino acid
        mutation relative to wild type and also sequences that failed the QC
        test; counts each variant in each population; and eliminates variants
        with fewer than 100 counts in the reference population (to reduce
        statistical uncertainty).
  - type: Heading
    id: sec013
    depth: 2
    content:
      - Sequencing analysis
  - type: Paragraph
    content:
      - 'To derive the mutational landscapes we compute the frequency '
      - type: Emphasis
        content:
          - P
          - type: Superscript
            content:
              - 'i,j'
      - ' of each mutant relative to wild-type in the selected and reference pools, where '
      - type: Emphasis
        content:
          - i
      - ' is the position and '
      - type: Emphasis
        content:
          - j
      - |2
         is the substitution, relative to wild-type:
  - type: MathBlock
    mathLanguage: mathml
    text: >-
      <mml:math display="block"
      id="M1"><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi
      mathvariant="normal">c</mml:mi><mml:mi
      mathvariant="normal">o</mml:mi><mml:mi
      mathvariant="normal">u</mml:mi><mml:mi
      mathvariant="normal">n</mml:mi><mml:mi
      mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>w</mml:mi><mml:mi>i</mml:mi><mml:mi>l</mml:mi><mml:mi>d</mml:mi><mml:mo>−</mml:mo><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math>
  - type: Paragraph
    content:
      - >

        where count is the number of reads for each mutant. The selection
        coefficients are then computed as the ratio:
  - type: MathBlock
    mathLanguage: mathml
    text: >-
      <mml:math display="block"
      id="M2"><mml:msup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mo
      stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo
      stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo
      stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo
      stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math>
  - type: Paragraph
    content:
      - |-

        where 
      - type: Emphasis
        content:
          - selected
      - ' refers to the top 15% binding population and reference refers to the reference population (Expression). The resulting '
      - type: Emphasis
        content:
          - S
          - type: Superscript
            content:
              - 'i,j'
      - ' values are then transformed to '
      - type: Emphasis
        content:
          - −ln
      - |2
         enrichment values:
  - type: MathBlock
    mathLanguage: mathml
    text: >-
      <mml:math display="block"
      id="M3"><mml:mo>−</mml:mo><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mo>(</mml:mo><mml:msup><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math>
  - type: Heading
    id: sec014
    depth: 2
    content:
      - Computational methods
  - type: Paragraph
    content:
      - >-
        All Rosetta design simulations used git version
        fb77c732b4f08b6c30572a2ef7760ad3bb4535ca of the Rosetta biomolecular
        modeling software, which is freely available to academics at 
      - type: Link
        target: 'http://www.rosettacommons.org/'
        content:
          - 'http://www.rosettacommons.org'
      - >-
        . Position-Specific Scoring Matrices (PSSM) for designed antibodies
        against VEGF (PDB: 2FJG) and against QSOX1 (PDB: 4IJ3) were collected as
        described in ref. [
      - type: Cite
        target: pcbi-1007207-ref038
        content:
          - '38'
      - '] and are distributed with the Rosetta release. RosettaScripts ['
      - type: Cite
        target: pcbi-1007207-ref067
        content:
          - '67'
      - '] and command lines are available in Supplemental Data. As in the '
      - type: Emphasis
        content:
          - AbDesign
      - ' method ['
      - type: Cite
        target: pcbi-1007207-ref038
        content:
          - '38'
      - >-
        ], separate PSSMs were generated for CDRs 3 and for CDRs 1, 2 and the
        framework by aligning structurally similar antibodies in the PDB and
        selecting only sequences that did not exhibit gaps relative to the query
        sequence; furthermore, a strict cutoff of ≤ 0.5 Å backbone-carbonyl rmsd
        was used to eliminate structurally divergent sequences. Thus, the PSSMs
        were only based on structural considerations and not on sequence
        homology or source organism.
  - type: Paragraph
    content:
      - >-
        We refined each bound PDB structure by four iterations of side-chain
        packing and side-chain and backbone minimization, saving the
        minimum-energy structure. Computational mutation scanning was applied to
        the refined structure using the FilterScan filter in Rosetta [
      - type: Cite
        target: pcbi-1007207-ref024
        content:
          - '24'
      - >-
        ]. At every position, each allowed mutation (that is, every amino acid
        identity with PSSM score ≥-1) was modeled singly against the background
        of the refined structure. Protein side chains within 8 Å of the modeled
        mutation were repacked, and side-chain and constrained backbone
        minimization were used to accommodate the mutation. The energy
        difference between the refined structure and the optimized configuration
        of the single-point mutant was calculated using the talaris2014 energy
        function [
      - type: Cite
        target: pcbi-1007207-ref068
        content:
          - '68'
      - >-
        ]. The energy threshold used to define the tolerated mutation space was
        +1 R.e.u. We next enumerated all possible combinations of mutations
        against VEGF (203,835 models) and against QSOX1 (491,235 models),
        modeled them in Rosetta and relaxed them by sidechain packing and
        sidechain, backbone and rigid-body minimization with harmonic backbone
        coordinate restraints. Designs were ranked based on their energy and the
        top 18 designs differing by 4–10 mutations relative to one another
        (VEGF) (
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s008'
            content:
              - S2 Table
      - >-
        ) and the top 20 designs differing by 3–14 mutations relative to one
        another (QSOX1) (
      - type: Strong
        content:
          - type: Link
            relation: supplementary-material
            target: '#pcbi-1007207-s009'
            content:
              - S3 Table
      - ) were selected for experimental characterization.
  - type: Heading
    id: sec015
    depth: 2
    content:
      - The AbLIFT web-server
  - type: Paragraph
    content:
      - >-
        The web-server implements several improvements relative to the method
        used to design the G6 and h492.1 variants [
      - type: Cite
        target: pcbi-1007207-ref041
        content:
          - '41'
      - >-
        ]. In the AbLIFT web-server, the multiple-sequence alignment used to
        construct the PSSM is first filtered to eliminate all loops and
        secondary-structure elements that exhibit any gaps relative to the query
        sequence. Furthermore, the web-server implements more accurate atomistic
        scoring and enables greater user control: it uses the recent Rosetta
        energy function ref15 [
      - type: Cite
        target: pcbi-1007207-ref069
        content:
          - '69'
      - >-
        ] with improved electrostatics and solvation potentials relative to the
        previous Rosetta energy function talaris and allows the user to manually
        modify the tolerated sequence space (for instance, based on prior
        experimental data or to eliminate potential immunogenic sequence
        signatures). Accordingly, ΔΔ
      - type: Emphasis
        content:
          - G
      - ' and PSSM cutoffs may be different from those used to in the designs described in the paper, and the web server provides user control over these parameters.'
  - type: Heading
    id: sec016
    depth: 2
    content:
      - Bacterial expression and purification (D44.1 and D44.1
      - type: Superscript
        content:
          - des
      - )
  - type: Paragraph
    content:
      - >-
        The design and wild-type were transformed into RH2.2 plasmid for
        expression as Fabs, where the heavy chain was N-terminally His-tagged
        and the light chain was expressed as a separate protein. Both chains
        contain a secretion sequence for direction to the periplasmic space,
        where they fold and dimerize. Restriction-free cloning was done using
        Kapa HiFi Hotstart Readymix (Kapa Biosystems) according to the
        manufacturer’s protocol.
  - type: Paragraph
    content:
      - >-
        Cells were induced with 1 mM IPTG at OD600 = 0.6, transferred to 20°C,
        and harvested after 20 h. The cells were then resuspended in buffer A
        [20 mM phosphate buffer pH 6.2, 150 mM NaCl] and sonicated. The
        supernatant was harvested by centrifugation (20,000 × 
      - type: Emphasis
        content:
          - g
      - >-
        , 1 h), filtered, and loaded on HiTrap TALON crude 1 ml column (GE
        Healthcare). Then it was washed with 15–20 bed volumes of buffer A, and
        then eluted with buffer B [20 mM phosphate buffer pH 6.2,150 mM NaCl,
        150 mM imidazole]. Imidazole was removed from the eluate by dialysis
        against Buffer C [20 mM Hepes buffer pH 7,150 mM NaCl] (1:400). The
        sample was then concentrated (Amicon Ultra-15 Centrifugal Filter; Merck)
        and purified by gel filtration in buffer C over a HiLoad 16/600 Superdex
        200 pg column.
  - type: Heading
    id: sec017
    depth: 2
    content:
      - 'Secreted IgG (G6, G6'
      - type: Superscript
        content:
          - des13
      - ) and Fab (D44.1
      - type: Superscript
        content:
          - des
      - ) production in suspension
  - type: Paragraph
    content:
      - >-
        Antibodies were expressed in suspension-HEK293F cells, grown in
        FreeStyle medium (Gibco), in a shaking incubator (115 rpm), at 37°C, in
        a controlled environment of 8% CO
      - type: Subscript
        content:
          - '2'
      - >-
        . The variable regions of the different heavy and light chains were
        cloned separately, upstream of IgG1 human Ab scaffolds, into p3BNC
        plasmids. Transfections were done using linear 40 kDa polyethyleneimine
        (PEI) (Polysciences) at 3 mg of PEI per 1 mg of plasmid DNA per 1 L of
        culture, at a cell density of 1 million cells/ml. Growth media were
        collected after 5–7 days and separated from cells by centrifugation at
        600 x g. Media were then supplemented with 0.02% (wt/vol) sodium azide
        and 0.1 mM PMSF and further clarified by centrifugation at 16,840 x g
        for 30 min.
  - type: Heading
    id: sec018
    depth: 2
    content:
      - 'Fab production (D44.1, G6, G6'
      - type: Superscript
        content:
          - des1
      - ', G6'
      - type: Superscript
        content:
          - des13
      - )
  - type: Paragraph
    content:
      - >-
        Adherent HEK293T cells were cotransfected with genes encoding the light
        and heavy chain Fabs (heavy chain fused to C-terminal His tag) in p3BNC
        plasmids using linear PEI as a transfection reagent (12.5 μg/12.5 μg/50
        μg, respectively, per 15-cm plate). Seventy-two hours post-transfection,
        the medium containing the secreted protein was collected (~250 ml).
  - type: Heading
    id: sec019
    depth: 2
    content:
      - 'Fab purification (D44.1, D44.1'
      - type: Superscript
        content:
          - des
      - ', G6, G6'
      - type: Superscript
        content:
          - des1
      - ', G6'
      - type: Superscript
        content:
          - des13
      - )
  - type: Paragraph
    content:
      - >-
        The filtered medium was concentrated to ~200 ml using a diafiltration
        device (QuixStand Benchtop System; GE Healthcare). The medium
        composition was exchanged to buffer A [50 mM Tris pH 8 and 150 mM NaCl]
        using the same device. This was loaded on a HisTrap HP 5 ml column (GE
        Healthcare). Washed with 15 bed volumes of 20 mM Tris pH 8, 150 mM NaCl
        and 10mM imidazole and was eluted with 20 mM Tris pH 8, 150 mM NaCl and
        250 mM imidazole. Imidazole was removed from the eluate by dialysis
        against Buffer A (1:400). The sample was then concentrated (Amicon
        Ultra-15 Centrifugal Filter; Merck) and purified by gel filtration in
        buffer A over a HiLoad 16/600 Superdex 200 pg column.
  - type: Heading
    id: sec020
    depth: 2
    content:
      - 'Apparent '
      - type: Emphasis
        content:
          - T
      - type: Subscript
        content:
          - type: Emphasis
            content:
              - m
      - ' and aggregation onset measurements'
  - type: Paragraph
    content:
      - >-
        The apparent melting temperature of the antibodies was determined by
        Prometheus NT. Plex instrument (NanoTemper Technologies), a label-free
        method. Fabs obtained from secreted Fab production in adherent cells
        (D44.1, G6, G6
      - type: Superscript
        content:
          - des1
      - ', G6'
      - type: Superscript
        content:
          - des13
      - ) and from production in suspension (D44.1
      - type: Superscript
        content:
          - des
      - >-
        ) were diluted to 0.2 mg/ml (in 20 mM Hepes pH 7 and 50mM NaCl for
        anti-lysozyme antibodies and in 20 mM Hepes pH 7.5, 150 mM NaCl for anti
        VEGF antibodies). The temperature was ramped from 25°C to 100°C at
        0.05°C/s, and both 
      - type: Emphasis
        content:
          - T
      - type: Subscript
        content:
          - type: Emphasis
            content:
              - m
      - ' and aggregation-onset temperature were measured.'
  - type: Heading
    id: sec021
    depth: 2
    content:
      - Surface-plasmon resonance
  - type: Paragraph
    content:
      - >-
        Surface plasmon resonance experiments on the anti-lysozyme (D44.1 and
        D44.1
      - type: Superscript
        content:
          - des
      - ' expressed in bacteria) and anti-VEGF antibodies (G6, G6'
      - type: Superscript
        content:
          - des1
      - ' and G6'
      - type: Superscript
        content:
          - des13
      - ' expressed in adherent cells) were carried out on a Biacore T200 instrument (GE Healthcare) at 25°C with HBS-N EP+ [10 mM Hepes, 150 mM NaCl, 3 mM EDTA, 0.005% vol/vol surfactant P20 (pH 7.4)]. For binding analysis, 1,000–1,600 response units (RU) of Fab were captured on a CM5 sensor chip. Samples of different protein concentrations were injected over the surface at a flow rate of 30 μL/min for 240 s, and the chip was washed with buffer for 2,000 s. If necessary, surface regeneration was performed with 30 s injection of 50 mM NaOH (D44.1'
      - type: Superscript
        content:
          - des
      - >-
        ) or 10 mM NaOH (VEGF antibodies) at a flow rate of 30 μL/min. One flow
        cell contained no ligand and was used as a reference. The acquired data
        were analyzed using the device’s software, and kinetic fits were
        performed.
  - type: Heading
    id: sec022
    depth: 2
    content:
      - 'IgG Western blot analysis (G6, G6'
      - type: Superscript
        content:
          - des1
      - ', G6'
      - type: Superscript
        content:
          - des13
      - )
  - type: Paragraph
    content:
      - >-
        HEK293T cells were seeded on a 24-well plate pre-coated with
        poly-L-lysine at 120,000 cells/well. The next day, cells were
        transfected with 1 μg DNA mixture consisting of 200 ng pLXN plasmid
        encoding Luciferase, 400 ng of a plasmid encoding the light chains and
        400 ng of a plasmid encoding the heavy chains of the designated
        antibodies. Each transfection was carried in 100 μl DMEM in which 2 μg
        of linear 40,000 Da PEI (Polysciences) per μg of DNA were mixed. The
        transfection mixture was added to cells, for a total volume of 400 μl
        DMEM per well. 4 hours after transfection, cells were washed and fresh 1
        ml DMEM with 1% penicillin and streptomycin, glutamine and non-essential
        amino acids was applied. 72 hours post-transfection supernatant was
        separated from cells and the cells were resuspended in 500 μl PBS. A
        sample of 100 μl from the suspended cells from each well was transferred
        to 96-well white plates (Nunc) with 100 μl of Bright-Glo reagent
        (Promega) to quantify the level of luciferase as a proxy for the
        transfection efficiency. Adjusted volumes of supernatants based on the
        luciferase levels were loaded on a gradient gel (Bio-Rad) and run
        according to manufacturer's instructions. Semi-dry blotting was
        performed to a nitrocellulose membrane followed by blocking in 5% milk
        powder in TBST (0.1% Tween 20, 20 mM Tris pH 8.0, 150 mM sodium
        chloride) buffer for 30 min at room temperature. Donkey anti-human IgG
        conjugated to HRP (Abcam) was used to detect the human IgG scaffold for
        1 h at room temperature.
  - type: Heading
    id: sec023
    depth: 2
    content:
      - Mass spectrometry sample preparation
  - type: Paragraph
    content:
      - >-
        Following IgG production in suspension (as described above), clarified
        media were aliquoted, snap frozen in liquid nitrogen and stored at
        -80°C. On the day of the measurements, samples were thawed and buffer
        exchanged into 1 M ammonium acetate, pH 7, using Micro Bio-Spin 6
        Columns (Bio-Rad). To break all disulfide bonds, antibodies were then
        reduced for 4 h at 37°C in the presence of 20 mM TCEP, followed by two
        consecutive buffer exchanges into 1 M and 150 mM ammonium acetate,
        respectively.
  - type: Heading
    id: sec024
    depth: 2
    content:
      - Native-mass spectrometry
  - type: Paragraph
    content:
      - >-
        Nanoelectrospray ionization (nano-ESI) MS experiments were performed on
        a modified Q-Exactive Plus Orbitrap EMR (Thermo Fisher Scientific,
        Bremen, Germany) [
      - type: Cite
        target: pcbi-1007207-ref070
        content:
          - '70'
      - >-
        ]. All spectra are shown without smoothing. The instrument was
        calibrated externally, using cesium iodide. Typically, an aliquot of 2
        μl protein solution was loaded into a gold-coated nano-ESI capillary
        prepared in-house, as previously described [
      - type: Cite
        target: pcbi-1007207-ref071
        content:
          - '71'
      - >-
        ], and sprayed into the instrument. Conditions within the mass
        spectrometer were adjusted to preserve noncovalent interactions. The
        source was operated in positive mode, the capillary voltage was set to
        1.7 kV, the capillary temperature was 180°C and argon was used as the
        collision gas in the higher-energy collision-induced dissociation (HCD)
        cell. MS spectra were recorded at a resolution of 10,000 and HCD voltage
        was set to 50 V, at trapping gas pressure setting of 3.9, which
        corresponds to HV pressure of 1.04 x 10
      - type: Superscript
        content:
          - −4
      - ' mbar and UHV pressure of 2.35 x 10'
      - type: Superscript
        content:
          - −10
      - ' mbar. Bent flatapole DC bias and axial gradient were set to 2 V and 25 V, respectively.'
  - type: Heading
    id: sec025
    depth: 2
    content:
      - Gas-phase stability assay
  - type: Paragraph
    content:
      - >-
        Antibody stability was monitored by tandem MS (MS/MS), at different HCD
        voltages. The 23
      - type: Superscript
        content:
          - +
      - ' charge state of the G6 and G6'
      - type: Superscript
        content:
          - des13
      - ' antibodies was isolated in the quadrupole, with an isolation window of 20 m/z, and the transmitted ions were subjected to collision-induced dissociation in the HCD cell, at a gradient of accelerating voltages ranging between 50–200 V. The relative abundance of the full IgG’s and the dissociated light chains, recorded at the different HCD voltages, was determined by measuring their peak heights. The total intensity of the light chains was calculated as the sum of intensities of their corresponding charge states. In each experimental condition, the total intensities of all the measured species were summed and referenced as 100% intensity. The relative intensity of each species was then calculated as a percentage of the total intensity. The stability assay was performed six times. Error bars represent standard deviation.'
  - type: Heading
    id: sec026
    depth: 2
    content:
      - Anti-QSOX1 antibody production
  - type: Paragraph
    content:
      - >-
        The coding sequences for variable domains of antibody 492.1 were fused
        to human antibody constant regions [
      - type: Cite
        target: pcbi-1007207-ref072
        content:
          - '72'
      - >-
        ]. Mutations were introduced by site-directed mutagenesis into the
        resulting hybrid antibody expression plasmids according to published
        procedures [
      - type: Cite
        target: pcbi-1007207-ref073
        content:
          - '73'
      - >-
        ]. Plasmids were transfected into suspension-adapted suspension-HEK 293F
        cells. The day before transfection, cells were split to 0.7 x 10
      - type: Superscript
        content:
          - '6'
      - ' cells/ml. For parallel expression of the parent hybrid antibody and the 20 variants, transfections were performed using 0.5 μg of each plasmid (heavy and light Ab chains) mixed with 3 μg PEI Max reagent (Polysciences Inc.) and incubated 20 min in 24-well tissue culture trays prior to addition of 1 ml cells per well. Plates were then agitated vigorously in a tissue culture incubator/shaker to prevent cell settling. After 4 days, cultures were transferred to microfuge tubes, and cells were pelleted by centrifugation at 500 x g for 10 min. Supernatants were transferred to fresh microfuge tubes, from which aliquots were taken for quantification of antibody expression and activity. For purification of selected Ab designs, transfections were done in 40 ml volumes, and plasmid and PEI Max amounts were scaled up accordingly. Cultures were grown for 6 days, and Ab was purified from the supernatant by protein G affinity chromatography (GE Healthcare).'
  - type: Heading
    id: sec027
    depth: 2
    content:
      - QSOX1 dot blot and Western blot assays
  - type: Paragraph
    content:
      - >-
        Relative antibody concentrations were determined from culture
        supernatants by dot and Western blotting. Blotting was conducted in
        triplicate for each of two biological replicates. For dot blots, 2 μl of
        each supernatant was spotted onto nitrocellulose membranes. Membranes
        were then covered with a blocking solution of PBS containing 0.1% Tween
        (PBS-T) and 5% bovine serum albumin (BSA) and gently agitated for 1 h at
        room temperature. For western blots, 10 μl of each supernatant was
        applied with non-reducing gel loading buffer to 10% SDS polyacrylamide
        gels. After electrophoresis, proteins were transferred to
        nitrocellulose, and the membranes were incubated in PBS-T with 5% BSA
        under gentle agitation. For both dot and Western blots, horseradish
        peroxidase-conjugated antibody recognizing human Fc was added to the
        blocking solution after the first hour, and incubation/shaking was
        continued for another 45 min. The membrane was then washed three times
        for 5 min each with PBS-T, and the blot was developed using SuperSignal
        West Pico (ThermoFisher) chemiluminescent substrate. Dot and band
        intensities were recorded on a ChemiDoc XRS+ system (Bio-Rad).
  - type: Heading
    id: sec028
    depth: 2
    content:
      - QSOX1 inhibition assays
  - type: Paragraph
    content:
      - >-
        QSOX1 inhibition assays were conducted by using
        5,5-dithio-bis-2-nitrobenzoic acid (DTNB) to quantify the remaining
        dithiothreitol (DTT) after incubation with purified recombinant QSOX1
        and HEK293 culture supernatants or purified antibody. Culture
        supernatants (25 μl) were mixed in a clear, flat-bottom, 96-well plate
        with 12.5 μl of 40 nM QSOX1, and reactions were initiated by injection
        of 12.5 μl 600 μM DTT (final concentrations 10 nM QSOX1 and 150 μM DTT).
        Reactions were stopped after 30 min by adding 150 μl 500 μM DTNB, and
        absorbance at 412 nm was measured after 5 min in a Tecan microplate
        reader.
  - type: Paragraph
    content:
      - >-
        Purified antibody variants were quantified by absorbance at 280 nm after
        dilution into 6 M guanidine dissolved in PBS, using an extinction
        coefficient of 187,000 M
      - type: Superscript
        content:
          - '-1'
      - cm
      - type: Superscript
        content:
          - '-1'
      - >-
        . Purified antibodies (12.5 μl) at concentrations of 40 nM, 100 nM, and
        200 nM were mixed in a 96-well plate with 12.5 μl 100 nM QSOX1, and
        reactions were initiated by injection of 25 μl 600 μM DTT (final
        concentrations 25 nM QSOX1, 300 μM DTT, and 10, 25, or 50 nM antibody).
        Reactions were stopped after 20 min by adding 150 μl 500 μM DTNB, and
        absorbance at 412 nm was measured after 5 min. Background-subtracted
        absorbance readings were normalized relative to the uninhibited and
        fully inhibited reactions (the latter mimicked by leaving QSOX1 out of
        the reaction), and results were plotted in 
      - type: Link
        relation: fig
        target: '#pcbi-1007207-g005'
        content:
          - Fig 5C
      - ' as the relative inhibitory activity.'
  - type: Heading
    id: sec029
    depth: 1
    content:
      - Supporting information
  - S1 Fig
  - type: Heading
    id: sec029
    depth: 1
    content: []
  - type: Paragraph
    content:
      - type: Strong
        content:
          - a. Mutational tolerance mapping of the anti-lysozyme antibody D44.1.
      - ' Mutations that were enriched, depleted, or had insufficient data in deep sequencing are marked in blue, red, and gray respectively. Wild type amino acids are indicated in one-letter codes for each position. Disulfide-bonded cysteines are marked in black triangles, and light-heavy chain interface positions in which point mutations exhibited over threefold enrichment relative to wild type, are marked in pink triangles. '
      - type: Strong
        content:
          - b.
      - ' Qualitative binding titrations using yeast display for D44.1, D44.1'
      - type: Superscript
        content:
          - des
      - >-
        , and seven point mutants that comprise D44.1des using yeast surface
        display. Binding fluorescence intensities are relative to the highest
        concentration of 1 μM lysozyme.
  - type: Paragraph
    content:
      - (TIF)
  - S2 Fig
  - type: Heading
    id: sec029
    depth: 1
    content: []
  - type: Paragraph
    content:
      - type: Strong
        content:
          - a.
      - ' The crystal structure of D44.1'
      - type: Superscript
        content:
          - des
      - ' (yellow and green for heavy and light chains, respectively) shows high accuracy relative to the computational design (lavender). Electron density at 2 σ. '
      - type: Strong
        content:
          - b.
      - ' Crystallographic analysis of D44.1'
      - type: Superscript
        content:
          - des
      - ' shows high agreement with D44.1 (0.7 Å Cα root-mean-square deviation), including in the orientations of binding-surface residues (sticks; D44.1 in gray).'
  - type: Paragraph
    content:
      - (TIF)
  - S3 Fig
  - type: Heading
    id: sec029
    depth: 1
    content:
      - >-
        Computational mutation tolerance mapping enriches for low-energy
        designs.
  - type: Paragraph
    content:
      - >-
        (blue) the distribution of Rosetta energies relative to G6 of a
        selection of >150,000 unique multipoint mutants at 11 positions encoded
        in the tolerated sequence space computed by PSSM (≥-1) and ΔΔ
      - type: Emphasis
        content:
          - G
      - ' (≤+1 R.e.u.) filters. (green) a random set of multipoint mutants at 30 vL-vH interface (all interface positions were allowed), where any of the 19 amino acid mutations was allowed at each mutated position. In both sets, the same number of multipoint mutants was analyzed, and the same distribution of the number of mutations relative to G6 was implemented. 37% of the multipoint mutants had energies that were more favorable than G6, whereas less than 0.03% of the random mutants had more favorable energies than G6. Thus computational mutation tolerance mapping enriches for improved mutants by over 1,100-fold relative to random multipoint mutations.'
  - type: Paragraph
    content:
      - (TIF)
  - S4 Fig
  - type: Heading
    id: sec029
    depth: 1
    content:
      - 'G6, G6'
      - type: Superscript
        content:
          - des1
      - ', and G6'
      - type: Superscript
        content:
          - des13
      - ' Fab expression and purification.'
  - type: Paragraph
    content:
      - >-
        (a) Following Ni-NTA purification, G6 exhibits the expected band at 50
        kDa, and additional bands at approximately 100 kDa, indicative of sample
        heterogeneity. G6
      - type: Superscript
        content:
          - des13
      - ' and G6'
      - type: Superscript
        content:
          - des1
      - >-
        , by contrast, primarily elute at the 50 kDa size range with no
        detectable higher-mass bands. (b) Designs G6
      - type: Superscript
        content:
          - des13
      - ' and G6'
      - type: Superscript
        content:
          - des1
      - ' after gel filtration run at their expected sizes. The status of reducing conditions (without DTT and boiling) is indicated at the bottom of the gels.'
  - type: Paragraph
    content:
      - (TIF)
  - S5 Fig
  - type: Heading
    id: sec029
    depth: 1
    content:
      - Secreted full-length IgG1 G6 and G6
      - type: Superscript
        content:
          - des13
      - ' antibodies were reduced and analyzed by native mass-spec directly from the growth medium.'
  - type: Paragraph
    content:
      - >-
        Upper panels show the full spectra. Charge state series of the two
        antibodies are labeled by dark blue and light blue circles,
        respectively. The +23 charge state of each antibody was isolated in the
        quadrupole and subjected to a gradual elevation of collision voltage in
        a stepwise manner, ranging from 50 to 200 V. Light chains, which
        gradually dissociated from the intact antibodies, are labeled the by red
        and orange circles.
  - type: Paragraph
    content:
      - (TIF)
  - S6 Fig
  - type: Heading
    id: sec029
    depth: 1
    content:
      - >-
        All 20 h492.1 designs were expressed, and their activities from culture
        supernatants were measured as described in the methods.
  - type: Paragraph
    content:
      - >-
        The highest values in the blot reflect the greatest amounts of substrate
        remaining at the end of a QSOX1 sulfhydryl oxidase activity assay,
        indicating the greatest inhibition of QSOX1 by the antibody. Due to
        differences in expression levels (
      - type: Link
        relation: fig
        target: '#pcbi-1007207-g005'
        content:
          - Fig 5A and 5B
      - >-
        ), inhibitory activity in this experiment reflects a combination of
        expression yield and intrinsic activity. The designs with results
        plotted in color (yellow and pink) were expressed in larger volumes,
        purified, and compared quantitatively for inhibitory activity compared
        to the parental 492.1 antibody purified from a hybridoma (
      - type: Link
        relation: fig
        target: '#pcbi-1007207-g005'
        content:
          - Fig 5C
      - ).
  - type: Paragraph
    content:
      - (TIF)
  - S1 Table
  - type: Heading
    id: sec029
    depth: 1
    content:
      - 'Data collection and refinement statistics for D44.1des, PDB code 6GC2.'
  - type: Paragraph
    content:
      - (XLSX)
  - S2 Table
  - type: Heading
    id: sec029
    depth: 1
    content:
      - >-
        The mutated positions and identities in G6 designs, colored according to
        their physicochemical properties and sorted by normalized fluorescence
        value (measured by yeast display experiments).
  - type: Paragraph
    content:
      - (DOCX)
  - S3 Table
  - type: Heading
    id: sec029
    depth: 1
    content:
      - >-
        The mutated positions and identities in anti-QSOX1 492.1 designs,
        colored according to their physicochemical properties.
  - type: Paragraph
    content:
      - (DOCX)
  - S4 Table
  - type: Heading
    id: sec029
    depth: 1
    content:
      - >-
        Log-enrichment of the deep mutational scanning data of anti-lysozyme
        antibody D44.
  - type: Paragraph
    content:
      - >-
        Data retrieved from the deep mutational scanning analysis of enrichment
        over WT for single point substitutions.
  - type: Paragraph
    content:
      - (XLSX)
  - S1 Protocol
  - type: Heading
    id: sec029
    depth: 1
    content:
      - RosettaScript for refinement of structures retrieved from the PDB.
  - type: Paragraph
    content:
      - (TXT)
  - S2 Protocol
  - type: Heading
    id: sec029
    depth: 1
    content:
      - RosettaScript for single-point mutational scanning.
  - type: Paragraph
    content:
      - (TXT)
  - S3 Protocol
  - type: Heading
    id: sec029
    depth: 1
    content:
      - RosettaScript for combinatorial sequence design.
  - type: Paragraph
    content:
      - An example of a protocol for designing a specific combinatorial mutant.
  - type: Paragraph
    content:
      - (TXT)
  - S1 Text
  - type: Heading
    id: sec029
    depth: 1
    content:
      - DNA sequences of tested constructs.
  - type: Paragraph
    content:
      - (DOCX)
  - S2 Text
  - type: Heading
    id: sec029
    depth: 1
    content:
      - Amino acid sequences of G6 and G6des13 IgGs.
  - type: Paragraph
    content:
      - Protein sequences used in the mass spectrometry analyses.
  - type: Paragraph
    content:
      - (DOCX)
